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ABSTRACT 
Inflammation is established as a key factor in mediating the progression of a number of retinal 
degenerations, including both wet and dry age-related macular degeneration (AMD) [1-3]. 
MicroRNAs (miRNAs) are a class of endogenously occurring non-coding RNA (ncRNA) 
molecules that are gaining momentum as therapeutic targets for treating a number of human 
conditions [4-6] and have been identified to modulate inflammation [7]. The purpose of this 
study is to investigate the modulation of miRNAs in a model of retinal degeneration, the light 
damage model. MiRNA and their potential roles in mitigating retinal inflammation will also 
be investigated in animals treated with 670nm red light therapy.  
 
Albino rats raised in dim cyclic light conditions (5lux; 12hr on, 12hr off; controls) were 
exposed to bright continuous light (1000lux) for 24 hours and returned to dim light conditions 
for 0, 3 or 7 days. At each timepoint animals were culled and their eyes removed and processed 
either for histological analyses or RNA based analyses. For histology eyes were fixed in 4% 
paraformaldehyde, cryoprotected and sectioned to determine the photoreceptor cell death using 
TUNEL or perform immunohistochemistry experiments using Vimentin and IBA1 or in situ 
hybridisation for Ccl2 and miR-124-3p. RNA was extracted from dissected retinas, reverse 
transcribed and used for low density array and qPCR analysis to determine the expression 
changes of genes and miRNAs. Immortalised cell lines were also used for performing cell 
transfections and similar RNA based analyses as above.  
 
Intense light exposure for 24 hours led to differential expression of a number of miRNAs, 37 
of which were significantly modulated by 2-fold or more. Of those, 19 may potentially regulate 
the inflammatory immune response observed in the model. MicroRNAs -125-3p, -155, -207, -
xviii 
 
347, -449a, -351, and -542-3p are all upregulated at 24 hours of exposure along with peak 
photoreceptor cell death. The miRNAs -542-3p and -351 reached maximum expression at 7 
days after exposure, while -125-3p, -155, -207, -347, and -449 reached a peak expression at 3 
days. MiR-124-3p expression showed significant downregulation post intense (1000lux) light 
induced damage to the rat retina. Its expression was localized predominantly to the Müller glia 
and showed co-localisation with expression of a target gene, Ccl2 (which is a potent 
chemoattractant molecule responsible for targeted monocyte recruitment in the retina). 
Luciferase assays in MIO-M1 and HeLa cells confirmed direct binding between miR-124-3p 
and the CCL2-3’UTR. Additionally, in vitro overexpression of miR-124-3p in Müller cells 
using miRNA mimics significantly inhibited CCL2 upregulation post stimulation with 
inflammatory cues. Post mortem human tissue showed a similar expression profile for miR-
124-3p in the retina. Changes is miRNA expression were also seen in 670nm light treated 
retinas with or without bright light induced damage, along with the modulation of chemokine 
gene expression in the pre-treated retinas. Differential expression of miR-351 and miR-155 
was confirmed using qPCR, both of which are predicted to target inflammation related genes.  
The data indicate that miRNAs are involved in modulating the inflammatory immune response 
elicited during retinal degeneration. Indeed we found a number of potential candidates, 
including miR-124-3p, which could prove to be novel therapeutic interventions in mitigating 
retinal inflammation and the consequent photoreceptor death. 670nm light therapy mitigated 
retinal inflammation including the modulation of specific miRNAs in the retina.           
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CHAPTER 1: INTRODUCTION 
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1.1 GENERAL INTRODUCTION 
Sight is one of the primary senses in humans that plays a major role in our ability to perceive 
and interact with the surroundings and the world we live in. This makes it an essential sense 
which has a major impact on our quality of life. The retina is a neuronal tissue present at the 
posterior end of the eye which is responsible for converting light entering the eye to electrical 
signals which are interpreted by the brain as vision. Age-related macular degeneration (AMD) 
is a degenerative disorder of the retina which is the leading cause of irreversible blindness in 
those aged over 60 in the western world. It is a progressive retinopathy that affects the 
photoreceptors, retina pigment epithelium (RPE), Bruch’s membrane and the choroid 
predominantly in the central macular region, which is the region of the retina that mediates our 
high acuity and colour vision. AMD is a multifactorial disorder, involving complex interactions 
between environmental and genetic factors. Although, evidence accruing over the past decade 
has firmly bolstered the association of inflammatory dysregulation with the pathogenesis of 
AMD. There are currently no effective treatments targeting the inflammatory immune response 
implicated in AMD pathophysiology.   
MicroRNAs (miRNAs) are a new class of endogenously occurring molecules that have strong 
therapeutic potential for diseases such as AMD. They are abundant in the central nervous 
system (CNS) and may be key in modulating inflammation and as a result progression of retinal 
degenerations. Red-near infrared (R/NIR) light therapy is another novel form of therapy which 
has been gaining momentum with respect to potentially mitigating inflammation associated 
with retinal degenerations.      
In this chapter I will provide general information about the anatomical structures and function 
of the retina and the importance of inflammation in AMD pathogenesis, followed by a literature 
review encompassing the current knowledge of the role of miRNA in modulating inflammation 
and the beneficial effects of 670nm light therapy in the retina. 
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1.2 THE RETINA 
The retina is a laminated sensory tissue of the CNS that lines the posterior chamber of the eye 
and converts light to electrical signals through a process known as phototransduction. These 
signals are then sent to the visual centres of the brain via the optic nerve for further processing.  
The retina is considered part of the CNS as it essentially originates as an outgrowth of the 
developing brain during embryonic development. However true retinal development begins 
with the establishment of the optic vesicles which gives rise to the neural retina, optic stalk and 
the RPE. The neural retina contains the retinal progenitor cells (RPCs) which are responsible 
for the development of all seven retinal cell types. Each of the seven cell types exhibit a 
staggered differentiation cycle from the RPCs, with ganglion cells being the first to be produced 
while Müller cells being the last [8]. Each layer and cell type of the retina has a specific 
functional role (Figure 1.1). The mammalian retina has three distinct layers of neuronal cell 
bodies (‘nuclear layers’) and two layers of synapses (‘plexiform layers’). Photoreceptor cell 
bodies are located in the outer nuclear layer (ONL) with their light-receptive outer segments 
(OS) located deep to the ONL. The inner nuclear layer (INL) and ganglion cell layer (GCL) 
comprise second and third order neurons respectively. In the INL, horizontal, amacrine and 
bipolar cells modulate signals generated by the photoreceptors, while the ganglion cells (in the 
GCL) transmit these signals via the long axons of the optic nerve, to the brain. In addition, 
there are non-neuronal cell types associated with the retina including the macroglia (Müller 
cells and astrocytes) and microglia, which are the resident immunocompetent cells. The retinal 
pigmented epithelium (RPE) comprises phagocytic cells that are functionally integrated with 
the photoreceptors, and form a barrier between the CNS environment of the retina and the non-
neural environment of the adjacent choroid (Figure 1.1A, B). 
Photoreceptors are the light-sensing cells of the retina. Retinal degenerations commonly 
manifest through photoreceptor and RPE cell death, followed by remodelling in the inner layers 
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of the retina. There are 2 different types of photoreceptors - rods and cones, originally identified 
by the shape of their outer segments. While the basic structures of cone and rod photoreceptors 
are similar (Figure 1.1C), they can be distinguished by the shape of their outer segments, the 
type of photopigment expressed, the light sensitivity level and retinal distribution. Rod 
photoreceptors make up ~95% of the entire photoreceptor population in human retina and 97% 
in mice [9]. In both photoreceptor types the discs containing the light-sensitive opsins are 
organised inside the cytoplasm of the OS. In the rod outer segments the discs are not continuous 
with the cell membrane [10] and the photopigment they contain (rhodopsin) is highly sensitive, 
and mediates vision in low light conditions (scotopic/nocturnal). Cones have flattened discs 
which are continuous with the cell membrane [11] and include photopigments that mediate 
vision in daylight (photopic/diurnal) and colour perception. While rods are more sensitive to 
light, cones have faster photoresponses and adaptative properties [12]. 
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Figure 1. 1 Basic structure of the retina and photoreceptors 
Retina is the light sensing tissue lining the back of the eye. (A) Histological section of the 
mammalian retina stained with hematoxylin and eosin dyes, showing the cell nuclei (purple) 
and cytoplasm (pink). (B) A schematic diagram showing the interactions between the different 
layers and cell types of the retina. (C) Schematic diagram of the mammalian rod and cone 
photoreceptor indicating the structural differences. NFL; nerve fibre layer. GCL; ganglion cell 
layer. IPL; inner plexiform layer. INL; inner nuclear layer. OPL; outer plexiform layer. ONL; 
outer nuclear layer. IS; inner segment. OS; outer segment. RPE; retinal pigment epithelium.  
Images adapted from: 
A. http://www.eperimentica.com/services/tissue-processing/mouse-retina-he.   
B. Gray, H, Anatomy of the human body, 20th edition (1918). Lea and Febiger. 
C. Veleri, S, Lazar C.H, Chang, B, Seiving P.A, Banin, E and Swaroop, A. Biology and 
therapy of inherited retinal degenerative disease: insights from mouse models 
(2015). Disease models & mechanisms. 
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Phototransduction (i.e. the chemical cascade responsible for conversion of light to electrical 
signal) takes place in the outer segments, where the light absorbing opsins are located. 
Membranes infused with photopigments and arranged as stacked discs [13, 14] span the entire 
length of the outer segment, to maximize the probability of capturing a photon.  The outer 
segments are devoid of cellular protein synthesis machinery. Therefore metabolites, proteins 
and lipids must pass from the inner segments through the cilium, to reach the outer segment. 
The inner segment is an extension of the photoreceptor soma and is arranged into two sections, 
the mitochondria-rich ellipsoid and the myloid containing the other subcellular organelles, 
including the Golgi apparatus, smooth endoplasmic reticulum, microtubules and the other 
subcellular organelles. Outer plexiform layer is comprised of the axon terminals of the 
photoreceptors (a.k.a cone ‘pedicles’ or rod ‘spherules’) where they form synapses with the 
horizontal and bipolar cells. Hence, the electrical signals generated due to photon detection by 
the photoreceptors travel passively through the photoreceptor to the pedicle/spherules, and 
regulate glutamate release from the axon terminals.  
In the overall anatomy of the retina, rod photoreceptors are in abundance and far outnumber 
the presence of cone photoreceptors. However, in humans and primates, the retina contains a 
specialization known as the macula lutea, which is located to the temporal side of the optic 
nerve (Figure 1.2A). The macula contains a yellow pigment and acts as a filter of potentially 
damaging short wavelength light [15]. The highly specialized fovea centralis (or fovea) is 
central in the macula, and is characterised by having a peak density of cone photoreceptors and 
no rod photoreceptors or cones that are sensitive to short wavelength light (Figure 1.2B). The 
fovea is the primary contributor to our colour perception and high visual acuity. 
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Figure 1. 2 Distribution of rods and cones in the human retina 
Representative fundoscopic image of the human retina showing the localisation of the highly 
specialised macular, foveal region as well as the optic disc (blind spot) (A). Distribution of 
rod and cone cell densities along the horizontal meridian (B). In humans, Rod population 
dominates in the overall retina, but they are mainly distributed in the periphery, while cones 
are highly abundant in the central macular and foveal region.    
Images adapted from: 
A. Mikael, H. Medical gallery of Mikael Häggström (2014). Wikiversity Journal of 
Medicine. 
B. Osterberg, G, Topography of the layer of rods and cones in the human retina 
(1935). Acta Ophthalmologica (Suppl.) 6, 1-103.  
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1.2.1 IMMUNE PRIVILEGE 
Like the brain, the retina enjoys a degree of ‘immune privilege’ which to some extent protects 
CNS tissues from immune attack.  It has been argued that this evolutionary adaptation provides 
useful protection to CNS tissues, which have minimal regenerative potential [16]. In the retina 
the CNS microenvironment is maintained by the blood retinal barriers (BRB) [17] which 
minimize both the passive and active movement of cells, proteins and ions into the tissue, to 
preserve the extracellular milieu needed for efficient neuronal activity [18]. While the BRBs 
acts as a physical barrier against incessant recruitment of circulating leukocytes capable of 
causing more harm than good, it does not exclude the normal immune surveillance of the retina 
essential for maintaining regular neuronal function [19].      
Structurally there are two different BRB that exist in the neural retina: Inner and Outer [20-
22]. The inner barrier is located at the edge of the inner retina, formed between the endothelial 
cells of the retinal vasculature and a sheath of glial cell processes including astrocytes, Müller 
cells and microglia. The outer barrier is formed by the retinal pigment epithelium (RPE) 
monolayer. Both barriers comprise tight intercellular junctions present between adjacent 
endothelial / epithelial which restrict paracellular transport of proteins, ions and cells, as well 
as endocytotic cellular mechanisms that restrict transcellular transport [17].  Under non-
inflamed conditions, activated leukocytes from the circulation are capable of inducing local, 
transient breakdown of the BRB, to achieve extravasation into the neural tissue [23, 24]. 
However, in numerous retinal pathologies (including uveoretinitis, diabetic retinopathy, light-
induced retinopathy and AMD) there is significant, widespread breakdown of the BRBs, 
leading to altered permeability, changes in the retinal microenvironment, malfunction of 
neurons, and major tissue damage [17, 25, 26]. 
9 
 
1.2.2 AGE-RELATED MACULAR DEGENERATION 
AMD is the leading cause of blindness and vision loss among those aged over 60 years in 
developed nations [27]. It is an age-related retinopathy that leads to progressive focal 
degeneration of photoreceptors, RPE and Bruch’s membrane in the macular region of the 
retina. The disease is broadly categorised in two forms, known as ‘dry’ and ‘wet’.  
‘Wet’ or Neovascular AMD is associated with serious and acute vision loss, and is 
characterized by breach of the outer BRB by new blood vessels originating from the underlying 
choroid [28, 29]. These vessels penetrate Bruch’s membrane and can either proliferate and leak 
outside the RPE (‘occult’ neovascularization), or penetrate the RPE, proliferate and exude/leak 
into the retina. Giving this form of the disease its ‘wet’ annotation [30, 31] (Figure 1.3D). 
While the emergence of neovascular AMD is seen in only 10% of AMD cases, this form 
accounts for approximately 90% of severe vision loss. Current treatments for ‘wet’ AMD only 
include anti-angiogenic (anti-VEGF) drug based strategies. None of which provide long term 
relief from disease progression.  
The more common dry form of disease is characterized by formation of drusen (basal deposits) 
and RPE abnormalities including pigment changes and atrophy [28, 32] (Figure 1.3B). The 
significance of drusen in the pathogenesis of AMD remains unclear, although recently the 
association of drusen with ‘ghost vessels’ (i.e. remnants of previously healthy capillaries) in 
the choroid has been described [33, 34]. Advanced dry AMD is commonly referred to as 
geographic atrophy (GA) which, as the name suggests, is characterised by the widespread 
atrophy of photoreceptors and RPE at the macular region [35, 36], and causes moderate to 
severe vision loss [37, 38]. It is associated with reduced choroidal blood flow and choroidal 
degeneration [39]. GA is marked by a gradual expansion of the atrophic lesion resulting in 
progressive RPE atrophy, photoreceptor death and choroidal damage [40-42] (Figure 1.3C). 
While cones show signs of degeneration/damage earlier than rods, rods undergo cell death 
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more readily and are particularly vulnerable, with their deterioration contributing to the 
widening of the atrophic area [40, 43, 44]. The underlying mechanisms responsible for the 
expansion/progression of the lesion are largely unknown and currently no effective treatments 
are available to avoid the onset and limit progression [45]. While the aetiology of AMD in 
unclear, early events that feature in the pathology of outer retina include oxidative damage, 
inflammation and apoptosis [46].  
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Figure 1. 3 Major pathological features of AMD viewed by fundoscopy 
Representative fundoscopic images showing the major pathological aspects of AMD. (A) 
Normal, unaffected retina with no obvious anatomical changes. (B) Clusters of hard and soft 
drusen predominantly in the macular region, typically seen in early ‘dry’ form of the disease. 
(C) Development of a zone of severe atrophy in the macula leading to damage of RPE and 
photoreceptors is characteristic of atrophic AMD. (D) Formation of a prominent disciform scar 
due to proliferating vascular growth into the retina marks the end-stage or neovascular form to 
AMD. OD; Optic disc. 
Image adapted from: 
“Pinpointing the Earliest Defects in Age-Related Macular Degeneration.” PLoS Medicine 
3.1 (2006): e38. PMC. Web. 22 Sept. 2015. 
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1.2.2.1 INFLAMMATION IN AMD PATHOGENESIS 
The involvement of inflammatory processes and immunity in AMD have been looked at since 
the early 1900s [21, 47-50]. Several histological studies have identified the aggregation of 
leukocytes infiltrating through the choroid around disciform lesions in the macula [29, 51], 
while some studies using electron microscopy techniques have implicated the macrophages, 
lymphocytes and mast cells in breakdown of the Bruch’s membrane and RPE atrophy [47, 48]. 
Investigations using post mortem retinas has identified the close association of macrophages 
and other leukocytes in and around neovascular membranes, characteristic of wet AMD [49, 
52, 53]. Macrophages and giant multinucleated cells have also been identified in close 
proximity to atrophic AMD lesions [49, 54]. Additionally, histological studies of advanced 
AMD have demonstrated the increased presence of activated microglial cells in the ONL and 
subretinal spaces, slowly phagocytosing dead photoreceptor cells in the degenerating retina 
[55, 56]. 
Macrophage involvement has been investigated extensively in experimental animal models of 
AMD. Models using laser to induce choroidal neovascularization in mice have shown that 
systemic depletion of macrophages is associated with smaller retinal lesions and lower levels 
of VEGF expression [57, 58]. This suggests that macrophages are actively involved in 
photoreceptor degeneration and induction of neovascularization. This view is further supported 
by the demonstration of angiogenic activity of macrophages in culture [59].  
Recruitment of inflammatory cells during activation of the innate immune system occurs in 
almost all CNS pathologies [60, 61], including human retinal pathologies such as age-related 
macular degeneration (AMD) [54, 56, 62, 63], retinitis pigmentosa [56], late-onset retinal 
degeneration [56], retinal detachment [64], glaucoma [65-67], and diabetic retinopathy [66, 
68]. Similar features are expressed in experimental models of retinal degeneration, thus the 
results of animal studies in this area are particularly useful and informative [69].  
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Animal studies indicate that recruitment of inflammatory cells, particularly microglia and 
monocytes, may be useful in retinal defense [70]. However, it is also clear that widespread 
recruitment and activation of microglia damages neurons [71-74], most likely due to secretion 
of pro-inflammatory mediators and cytotoxic factors, including tumor necrosis factor (TNF)-
α, interleukin (IL)-1β [60, 75, 76], and release of nitric oxide [71, 77]. Moreover, microglial 
activation is directly implicated in models of neovascular AMD [78], diabetic retinopathy [79, 
80], glaucoma [81, 82], chronic photoreceptor degeneration in rds (retinal degeneration slow) 
mice [83], light-induced damage [74, 84-86] and photoreceptor apoptosis in vitro [74]. 
Although the exact mechanism underlying this targeted recruitment is unclear, a family of 
chemotactic molecules, the chemokines, have been implicated.  
1.2.2.2 CHEMOKINES   
Chemokines are a large family of molecules with potent chemoattractant properties in the CNS 
[87-90]. They are small molecules grouped according to the relative position of their first N-
terminal cysteine residues, into C (γ chemokines), CC (β chemokines), CXC (α chemokines), 
and CX3C (δ chemokines) families [87, 91]. Chemokine expression generates chemical ligand 
gradients that serve as directional cues for guidance of specific receptor-bearing leukocytes to 
sites of injury, and are also thought to aid in extravasation of those cells into tissues [92]. 
Chemokines exert their biological activity by acting as ligands for specialized cell surface 
receptors, part of the superfamily of seven transmembrane domain receptors consisting of C, 
CC, CXC, and CX3C receptor subclasses. Chemokine-receptor binding exhibits a high degree 
of redundancy in their interactions [87]. 
Increased expression of both α and β chemokines have been characterized in CNS disorders 
such as MS, AD, ischemia and brain trauma reviewed in [87, 90]. Recent gene expression 
studies of AMD donor eyes have shown upregulation of CCL2, CXCL1 and CXCL10 in both 
forms of the disease [93]. A number of studies using laser-induced CNV in mice and light-
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induced degeneration in albino rat have suggested a key role of CCL2 in both maintenance of 
retinal homeostasis as well as enhancing the severity during the degenerative process [59, 94-
98]. A recent report by Rutar and colleagues 2015 [99] showed the tissue localization of a 
number of chemokines with potential involvement in retinal pathogenesis, in the retina and 
adjacent tissues.  
1.2.2.3 ANIMAL MODEL OF RETINAL DEGENERATION – LIGHT INDUCED DAMAGE 
In the past decade, light-induced damage in albino rats has emerged as a well-established model 
to study retinal degeneration because of its high reproducibility, ease of use, rapid non-invasive 
induction and flexibility [100, 101]. The ability of bright light to induce retinal degeneration 
has been known for almost half a century. Noell (1966) first described the effect of sufficiently 
high intensity light on the rat retina. His study demonstrated that intense light exposure induces 
‘photochemical’ damage, inducing photoreceptor cell death and RPE dystrophy leading to 
vision loss [102]. Since this landmark study, light induced retinal degeneration has been 
extensively studied and its functional/histological effects investigated (reviewed in [96, 100, 
103-105]). It is well established that bright light exposure leads to photoreceptor cell death by 
apoptosis through oxidative damage generated by bleaching of the rhodopsin chromophore and 
the subsequent lipid peroxidation of DHA in their OS [106-108].  
Several studies indicate that light damage model of retinal degeneration has features in 
common with progressive dry AMD. These include: 
1. Susceptibility to photoreceptor death, RPE atrophy and choroidal changes in a specific 
location in temporo-superior retina [109-112], at the area centralis. This retinal 
specialisations is analogous to the macula lutea of the human retina, the region of 
targeted damage in AMD [113-115]. Interestingly, even though the area centralis in 
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the rat retina possesses more cones and ganglion cells, it is still substantially less than 
the fovea/macula of primate retina. 
2. Progressive photoreceptor cell death and RPE loss expanding outward from the site of 
initial acute damage for a prolonged period [105], resembling the increasing lesion size 
seen in advanced dry AMD [38]. 
3. Primary involvement of oxidative stress potentially leading to initial photoreceptor cell 
death and initiation of the inflammatory immune response, similar to that observed in 
AMD donor tissue [107, 116, 117].  
4. Involvement of inflammatory processes, including excessive leukocyte 
activation/recruitment [86, 118] and complement activation [119, 120], both of which 
have been implicated in AMD pathogenesis [49, 63, 121].  
 
Gene association studies identified a significant link between the Y402H sequence variant of 
complement factor H (CFH), a key inhibitor of the alternative complement pathway, and AMD 
susceptibility [122], along with other risk variants in complement components, including 
complement component 2 (C2) [123], complement factor B (CFB) [124] and complement 
component 3 (C3) [125, 126]. Among these C3, which is a vital component capable of driving 
the activation of all three complement pathways (refer to Figure 1.4), shows robust long-term 
upregulation in the light damage model where it is expressed by activated 
microglia/macrophages and deposited in the photoreceptor layer at the site of damage [119]. 
C3 is also a crucial mediator of the membrane attack complex (MAC), which has been reported 
in drusen deposits from donor eyes, making photoreceptors around the C3 expressing 
microglia/macrophages susceptible to cytotoxic damage [121, 127, 128]. Additionally, ablation 
of the complement factor D (CFD), an alternative pathway gene, has been shown to attenuate 
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photoreceptor death in the light damage model [120], suggesting involvement of alternative 
pathway activation similar to AMD.         
 
As a result of these overlapping features the LD model has become an effective model to study 
AMD and potentially a good system to investigate the efficacy of potential therapies for dry 
AMD. 
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Figure 1. 4 Overview of complement activation pathways 
Diagrammatic representation of the three complement activation pathways – classical, 
mannose binding lectin (MBL), and alternative. All of these converge in the proteolytic 
cleavage of complement component 3 (C3). 
Image taken from: 
Janeway et al, Immunology: The immune system in Health and Disease, (2005). Garland 
Science.    
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1.3 MICRO-RNA 
1.3.1 ORIGIN 
MicroRNAs are small non-coding RNA molecules present in both plants and animals [129]. 
They are typically ~19-24 nucleotide transcripts encoded by the genome, and are heavily 
conserved across many different species. Lin-4 was the first miRNA identified in animals in 
1993 during a screening of developmental mutants in C. elegans. It was observed that 
mutations in lin-4 lead to developmental defects in C. elegans due to a repeated L1 division 
during the later larval stages [130]. This work marked the beginning of miRNA research, which 
at first was considered to be an idiosyncrasy of the regulatory mechanism. This view changed 
in 2000 when another developmentally critical gene in C.elegans, let-7, was shown by two 
collaborating groups to encode a miRNA [131, 132]. Soon after, homologs of let-7 were found 
in flies and humans further bolstering the existence and importance of these novel regulatory 
molecules [133].       
To date thousands of miRNAs have been identified and characterised and documented in an 
open access online portal – www.miRbase.com.  
1.3.2 BIOGENESIS 
MiRNA genes are scattered in different regions across the genome. They can be present in the 
intron regions of protein coding genes, hence sharing the promoters of certain genes or regions 
far from the previously annotated genes. And in these regions, they can either exist as clusters 
yielding polycistronic transcripts or independently yielding monocistronic ones [134-138]. 
Moreover, with advent of highly sensitive next generation sequencing technologies it has been 
shown that there are a lot of miRNA redundancies in the genome, in that multiple copies of the 
same miRNA can be found in many different genomic locations. 
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A majority, if not all, miRNAs are transcribed by RNA polymerase II in the nucleus where 
they are initially processed as long primary transcripts (pri-miRNA) averaging ~1000 
nucleotides in length [139] (Figure 1.5). The pri-miRNA undergoes two consecutive cleavage 
events to generate the active, or mature form of the miRNA. The first cleavage takes place 
inside the nucleus, by an RNase III endonuclease called Drosha, which liberates an 
intermediate stem loop structure of about 60-100 nucleotides known as the precursor miRNA 
(pre-miRNA) [140-142]. Drosha cleaves both strands of the RNA duplex near the base of the 
primary stem loop in a RNase III typical staggered manner resulting in a 5’ Phosphate and ~2 
nt overhang at the 3’ end [143]. These pre-miRNAs are then actively exported to the cytoplasm 
by Exportin-5 where they undergo a second endonucleolytic cleavage event [144]. Dicer, also 
a RNase III endonuclease, first identifies the double-stranded portion of the precursor stem 
loop, potentially by the 5’ phosphate and the 3’ overhang, and then cleaves off the hairpin loop, 
typically two helical turns away, releasing a mature miRNA duplex with a 5’ phosphate and 3’ 
overhang on either end [135]. This processing by Drosha and Dicer helps distinguish these 
RNA strands from other breakdown RNAs [145-147]. From this mature miRNA:miRNA 
duplex, one strand (the lead strand) gets incorporated in the RNA induced silencing complex 
(RISC) [148], and is responsible for guiding the whole silencing machinery to the prospective 
mRNA targets (Figure 1.5).  
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Figure 1. 5 MicroRNA biogenesis and mode of action 
Schematic diagram showing the biogenesis and mode of action of mature microRNA (miRNA) 
sequences inside the cell. This canonical maturation of miRNAs includes two cleavage events 
(marked ‘1’ and ‘2’), catalysed by Drosha and Dicer respectively, resulting in the conversion 
of the long primary transcripts (Pri-miRNA) in the nucleus to small mature miRNA duplexes 
in the cytoplasm. Each strand of the mature duplex can then incorporate into the RNA induced 
silencing complex (RISC) and lead to gene regulation by either translational repression or 
messengerRNA (mRNA) degradation. 
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1.3.3 MODE OF ACTION 
The miRNAs inside the RISC complex interact with their target mRNAs by complementary 
base pairing, predominantly in the 3’UTR region of the target gene [142, 147, 149-151]. They 
direct downregulation of gene expression by one of two mechanisms: mRNA degradation, or 
translational repression. The choice of mechanism is determined by the degree of 
complementarity between the miRNA and its target mRNA [147]. Where perfect or near 
perfect complementarity occurs, the miRNA leads to mRNA cleavage/degradation (more 
commonly found in plants). However, imperfect complementarity results in translational 
repression, and is more commonly seen in animals [130, 131, 135] (Figure 1.5). In the case of 
mRNA cleavage, the miRNA-RISC remains intact after degradation, and is capable of 
recognising and destroying additional mRNA targets [152]. However, during translation 
repression the miRNA-RISC remains bound to its mRNA target and can either inhibit 
translation, resulting in no polypeptide formation, or hinder translation, resulting in a 
stunted/non-functional polypeptide formation which gets selectively degraded.        
1.3.4 BIOLOGICAL RELEVANCE 
MicroRNAs play crucial roles in regulation of diverse biological processes including organ 
development and homeostasis [131], cell proliferation, differentiation, apoptosis, and immune 
function [153, 154]. These micromanagers of gene expression regulate the mRNA expression 
profile post transcription, thereby providing the system an efficient way of coping with aberrant 
gene expression.  
Changes in miRNA abundance have been studied in disease since their discovery [155, 156]. 
To date miRNA deregulation and/or dysfunction has been implicated in almost every disease 
pathology including autoimmunity, viral infections, neurodegeneration, inflammation, cancer, 
cardiovascular, or neurological diseases [157-161].  
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MiRNAs are highly enriched in the CNS and have been shown to play different roles during 
its development, normal functioning and disease, with several miRNAs showing expression 
specifically in the CNS tissue/cells [162-165]. For instance, miRNAs -124, -9 and let-7b have 
been shown to play a role in modulating neurogenesis and neural differentiation [166, 167]. 
While downregulation of miR-124 has been linked to traumatic spinal cord injury [168]. 
Additionally, miR-9, -125b, -146a, -29a, -29b-1 have been implicated in Alzheimer’s disease 
[169, 170]; MiR-133b, -7 implicated in Parkinson’s disease [171, 172]; and miR-124, -132, -9 
implicated in Huntington’s disease [173, 174]. Being an extension of the CNS the retina serves 
as a good model system for characterising and validating miRNA gene regulation as: 
1. Its cellular architecture and cellular functions are well known. Hence, phenotypic 
changes as a consequence of specific miRNA manipulation can be clearly 
observed/demonstrated. 
2. It is easy to access and responsive to experimental, genetic manipulation. Hence, 
miRNA manipulations using modified oligonucleotide sequences can be achieved 
locally. 
3. Genetic manipulations leading to disruptions of the visual circuitry do not exhibit 
developmentally lethal effects. Hence, retina specific miRNA manipulations can be 
performed at different developmental stages to understand their specialised roles in 
neuronal cell biology. 
1.3.5 MIRNA AND INNATE IMMUNITY 
The innate immune response is the evolutionarily older of the two immune systems (‘innate’ 
vs ‘adaptive’) and constitutes the first line of defence against invading pathogens. The innate 
response is cell-mediated, involving monocytes, macrophages and dendritic cells and instigates 
the inflammatory response [175]. MiRNAs form an integral component of the regulatory 
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networks essential for fine tuning the innate immune processes. To date large number of 
miRNAs (listed in Table 1.1) have been implicated to play a role in innate immune processes.  
One of the first examples of miRNA regulation in immunity was shown in human monocytes 
stimulated with lipopolysaccharide (LPS). The study showed that signalling by TLRs induced 
a rapid up-regulation of miR-146a (among other miRNA changes), which acts as a negative 
feedback regulator of the signalling cascade, resulting in suppression of the immune response 
[176]. The same stimulation was later shown to induce another miRNA, miR-21, that 
suppressed the pro-inflammatory effect of the signalling [177]; it also showed up-regulation of 
miR-155, a well-established potent pro-inflammatory miRNA. MiR-155 is heavily induced in 
macrophages stimulated with both viral and bacterial antigens that activate different TLRs 
[176, 178-180] and exerts its pro-inflammatory effect by repression of negative regulators of 
inflammation. These include suppressor of cytokine signalling 1 (SOCS1), 
phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 (SHIP1) and certain anti-
inflammatory proteins [178, 181]. Moreover, miR-155 has been shown to increase the stability 
of TNF-α mRNA, thereby maintaining a pro-inflammatory environment [182]. Interestingly, 
mice deficient in miR-155 have decreased immune responses, while miR-155 overexpression 
leads to a myeloproliferative disorder resembling chronic inflammation, and haematopoietic 
cancers [183-185]. 
MicroRNAs can also regulate aspects of innate immune responses, either by targeting signal 
transduction proteins or the downstream transcripts in the inflammatory signalling pathways. 
TLRs or Toll like receptors are a class of transmembrane proteins that play an important role 
in innate immune response by recognizing structurally conserved molecules of microbial 
origin. Once activated (by ligand recognition) they initiate cell signaling cascades downstream. 
TLR2, 3 and 4 play important roles in propagating inflammation when triggered by their 
respective ligands of bacterial, parasitic origin. MiR-223, miR-105, miR-19, and let-7 family 
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members for instance, can directly target TLR2, TLR3 or TLR4 [180, 185-189], thereby 
inhibiting the ability of immune cells to engage with ligands specific to those receptors. MiR-
9 negatively regulates NF-κB-dependent inflammatory responses by suppressing expression of 
NFKB1 transcripts in LPS-stimulated neutrophils and monocytes [190]. While, miR-147 can 
act as a negative regulator of excessive inflammatory responses in macrophages [191] post its 
inducing via activation of TLR2, TLR3, or TLR4. 
  
25 
 
Table 1. 1 
MiRNAs in innate immunity 
MiRNA Targets Biological effect 
miR-9 NF-κB1 Negative regulator of TLR4 signaling 
miR-19 TLR2 Decreases TLR2 mediated 
inflammation 
miR-21 PDCD4, IL-12 p35 Negative regulator of TLR4 signaling 
miR-27b PPAR-γ Enhances response to LPS 
miR-105 TLR2 Decreases TLR2 mediated 
inflammation 
miR-106a IL-10 Decreases IL-10 
miR-125b TNF-α; IRF4 Diminishes inflammation; enhances 
  macrophage activation 
miR-145 TIRAP Inhibits TLR signaling 
miR-146a TRAF6, IRAK1, 
IRAK2 
Negative regulator of TLR signaling 
miR-155 AID; MyD88; 
TAB2; 
Enhances inflammation; 
 Pellino-1; IKKε; 
SHIP-1; 
negative feedback regulation 
 SOCS1; C/EBP-β  
miR-223 IKKα; Pknox1 Proinflammatory activation of 
macrophages 
Let-7i, let-7e TLR4 Downregulate inflammatory signaling 
 
Taken from: 
Liu, G., and Abraham, E. MicroRNAs in immune response and macrophage 
polarization (2013). Arteriosclerosis, thrombosis, and vascular biology. 33(2):170-177.  
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Additionally, reduced expression of the miRNAs Let-7i and miR-125b leads to enhanced 
inflammation in response to LPS and microbial infections [180, 187, 192, 193]. On the other 
hand, overexpression of miR-125b potentiates macrophage activation and enhances 
responsiveness to IFN-γ [194]. Taken together, the data suggest that different miRNAs act 
synergistically to fine tune of the inflammatory response, and that same miRNAs can have 
opposing effects in different cellular contexts. 
1.3.6 MIRNAS MEDIATING INFLAMMATION IN AMD: 
Although miRNAs have only recently become the focus of research in AMD, several miRNAs 
have been shown to contribute directly to pathological processes including angiogenesis, 
oxidative stress and inflammation. Specifically, miRs -146a, 125b, -155, -9 and -27 appear to 
show the most promise to date, with regard to managing inflammation in AMD. The key 
findings to date are as follows: 
1. Both miR-146a and -155 are up-regulated following stimulation with pro-
inflammatory cues such as LPS and cytokines (IL-1β, TNF-α), leading to regulation of 
both IL-6 and IL-8 expression [176, 179, 195-198]. MiR-125b is downregulated in 
LPS-treated macrophages and capable of targeting TNFα [180].   
2. MicroRNAs miR-9, -155, -146a and -125b are up-regulated in aging brain and retinal 
tissue. Of these miRs, -146a, -155 and 125b are capable of negatively regulating 
CFH expression by direct binding, thereby acting as potent promoters of the alternate 
complement pathway [199].  
3. MiR-27 is induced in LPS-treated human macrophages, and may contribute to both 
inflammation and neovascularisation in advanced ‘wet’ AMD [200, 201].  
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A recent seminal study implicated the role of noncoding (Alu) RNAs in advanced ‘dry’ AMD 
[202] showing that selective downregulation of Dicer-1, or anomalies in Dicer-1 expression in 
the RPE leads to accumulation of toxic double stranded Alu RNAs, and subsequent 
degeneration of the pigment epithelium. Anomalies in Dicer-1 also suggest anomalous 
processing of pri-miRNA affecting expression of a range of as yet unidentified genes. In 
addition, a recent study in the rodent light induced model of retinal degeneration identified 
modulation of a large proportion of ncRNA during degeneration [96].  
The field of miRNA therapeutics is rapidly gaining momentum along with the increasing 
knowledge of miRNA modulation in association with disease. A number miRNA-based 
therapeutics have already progressed from discovery to development with one currently in 
Phase 1 clinical trials while another already in Phase 2 [203, 204].   
 
1.4 PHOTOBIOMODULATION 
The therapeutic effects of sunlight have been explored for centuries in civilizations as old as 
the Roman, Greek and Chinese to treat a number of diseases [205, 206]. The first account of 
use of modern light therapy, however, was reported in the late 1800s when a Danish physician, 
Niels Finsen used crudely filtered red light to treat small pox and Lupus vulgaris. A pioneering 
use of the healing properties of light that earned him a Nobel Prize in 1903 [207, 208]. This 
work led to further exploration of clinical applications of light and the beginning of a new field 
of research known presently as either phototherapy or photobiomodulation (PBM), red light 
therapy, low level light therapy or near infrared (NIR) therapy. 
A Hungarian physician Endre Mester in the late 1960s showed the positive biostimulatory 
effects (including anti-inflammation, vasodilation, stimulated blood circulation and anti-
edema) in mice as a result of exposure to low level laser emitting near infrared (NR) light [209] 
28 
 
and further supported by studies in experimental animal models of wound healing and hair 
growth [210-212]. While the outcomes of these primary studies indicated high therapeutic 
potential, the mainstream clinical community has not accepted the use of ‘low level light 
therapy’ (LLLT) due to lack of proper controls and a lack of understanding of the mechanisms 
at play [213]. Additionally, a number of complicating factors come into play using lasers to 
produce low level light, including the inherent property of lasers to produce heat, leading to 
thermal damage to biological tissues, an inability to treat a large wound area while maintaining 
homogenous mean intensity/energy distribution due to its highly focused nature, inefficiency 
in producing different wavelengths of light simultaneously, and high setup and operational 
costs [214].  
The development of the light emitting diode (LED) and particularly the National Aeronautics 
and Space Administration’s (NASA) lightweight LED array system has provided an 
alternative, cost-effective non-coherent source for phototherapy [215]. Although NASA 
originally developed the LED array to facilitate growth of plants during space exploration 
missions, LEDs in the red to NIR spectrum were soon realized to possess significant wound 
healing properties [214, 216]. LED arrays can be manipulated to produce light at optimal 
intensity at specific wavelengths. In the red to NIR range these wavelengths penetrate skin and 
tissue to a depth of approximately 23cm without any heat emission, making them perfect 
candidates for therapeutic applications [216]. 
1.4.1 670NM RED LIGHT THERAPY 
The beneficial effects of monochromatic light in the red and near infrared (NIR) spectrum 
(Lambda = 600nm-1000nm) has been reported in a number of diseases over the past 30-40 
years. More recently, the use of 670nm wavelength light has attracted the interest of the global 
scientific community, and has been applied to a variety of human conditions, including 
cardiovascular [217], musculoskeletal [218, 219], and central nervous system (CNS) [220, 
29 
 
221]. Investigations using animal models of CNS disorders have demonstrated the beneficial 
effects of 670nm light treatment in optic nerve degeneration [222], long term effects of 
traumatic brain injury [223] and neuronal toxicity [224, 225]. 670nm light therapy is shown to 
alleviate clinical symptoms in an animal model of Experimental Autoimmune 
Encephalomyelitis (EAE) [226], and to reduce the incidence of oral mucositis (OM) in a cohort 
of pediatric bone marrow transplant patients [227]. Recent studies have also suggested that 
670nm light therapy reduces the severity of damage in experimental models of Alzheimer’s  
[228] and Parkinson’s disease [229]. 
In the last decade significant interest has accrued with respect to use of 670nm light irradiation 
in management of retinal injuries/pathologies. Studies have shown that 670nm light attenuates 
methanol-induced toxicity in rodents, laser-induced injury in primate retina and development 
of a retinal lesion in models of diabetic retinopathy [230-232]. Recently work from our group 
and others have demonstrated protective effects of 670nm light treatment on photoreceptor cell 
death in retinas exposed to bright white light [118, 233-236].  
Using microarray analyses in the light damage-induced model of retinal degeneration we have 
shown that pre-treatment with an optimal dose of 670nm irradiation maintains retinal function, 
and suppresses inflammation and oxidative stress-related gene expression [96]. Additionally, 
studies utilising CFH-/- mouse retina, aged rodent retina and light damaged rat retina have 
shown a reduction of pro-inflammatory processes by 670nm light treatment [236-239].  
1.4.1.1 MECHANISM OF ACTION  
Despite a growing body of evidence indicating effective clinical application for 670nm light 
therapy, the precise molecular mechanisms underlying its effect on mammalian cells/tissue 
remain unclear [240].  
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Light in the near infrared wavelength spectrum (~600-1000nm) is not absorbed by water, 
melanin and haemoglobin (Hb), the most abundant light absorbing molecules in biological 
systems (Figure 1.6) [241]. This allows for deeper penetration into tissues where the 
wavelengths can be absorbed by endogenous photo-acceptors such as porphyrins, flavoproteins 
and cytochromes [241-243]. Once absorbed, these wavelengths lead to excitation of the 
chromophores which then transfer their electrons to the nearby O2 molecules, generating potent 
signaling molecules known as reactive oxygen species (ROS) in the process [244, 245].  
It has been demonstrated that 670nm light is the optimal wavelength for absorption by 
cytochrome c oxidase (CCO), Complex IV of the electron transport chain [244, 246] - the rate 
limiting step in the oxidative phosphorylation pathway [247]. CCO contains 4 metal centres 
that catalyse the transfer of electrons from cytochrome c to Complex V, the final complex in 
the electron transport chain which drives production of ATP. Two of these centres are mixed-
valence copper components which are thought to be direct targets of 670nm irradiation (Figure 
1.7A) [248].  
It has been suggested that exposure to 670nm light modulates the redox state of CCO and 
increases CCO activity, leading to amplified flux across the electron transport chain and more 
efficient oxidative phosphorylation, and ATP [224]. A recent study has also documented the 
upregulation of CCO expression in an animal model of retinal degeneration as a result of 
670nm light irradiation (Figure 1.7B) [237]. An alternative hypothesis is that 670nm light 
dissociates NO from cytochrome c oxidase, thereby, releasing the enzyme from its inhibitory 
effect. Red-to-NIR irradiation is believed to stimulate a conformational change in CCO 
resulting in the release of NO [249, 250]. Free NO is then available to act as a signalling 
molecule to stimulate retrograde signalling between mitochondria and the nucleus, as well as 
increase oxygen consumption and enhance oxidative phosphorylation [251, 252].   
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Figure 1. 6 Absorption spectra of biological chromophores 
Shows the absorption spectra of abundant tissue chromophores, identifying the maximum 
tissue penetration window of light in the red and NIR wavelengths. This indicates the so-called 
“optical window” in biological tissue.  
Taken from: 
Hamblin, M. R and Demidova, T. N. Mechanisms of Low Level Light Therapy – an 
Introduction (2006). Proc SPIE. Vol 6140. 
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Figure 1. 7 Absorption spectrum of cytochrome c oxidase  
Cytochrome c oxidase (COO), a member of complex IV of the mitochondrial electron transport 
chain, catalyses the final transfer of electron to oxygen molecules thereby driving the 
production of energy as ATP (adenosine triphosphate) and is suggested to be the primary 
photoacceptor of 670nm light. (A) Shows the correlation between the absorption spectrum of 
the multivalent Cu (Copper) centres of COO and the cellular action spectrum in terms of DNA 
synthesis rate across the red-NIR light spectrum. (B) The overall absorption spectrum of CCO 
also correlates with its enzymatic activity and amount of cellular ATP. 
Images adapted from: 
A. Karu, T. Lasers in Medicine and Dentistry (2000). Chapter IV, 97-125. Russian 
Academy of Science.  
B. Wong-Riley, M.T.T, Liang, H. L, Eells, J. T et al. Photobiomodulation directly 
benefits primary neurons functionally inactivated by toxins: Role of cytochrome c 
oxidase (2004). The American Society for Biochemistry and Molecular Biology.  
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However, if accumulated in extremely high amounts this NO can be cytotoxic to the cells, as 
mentioned previously [71, 77]. 
Collectively, all cellular proteins that absorb 670nm light are believed to stimulate a cascade 
of other proteins or cell signaling molecules which are capable of modulating specific gene 
transcriptions. Gene expression studies indicate that treatment with 670nm light prior to a 
damaging stimulus enhances expression of genes associated with antioxidant protection, 
mitochondrial metabolism and cell proliferation, while suppressing pro-inflammatory, pro-
apototic genes [96, 253, 254]. In the retina 670nm light therapy seems to exert a beneficial 
effect by minimizing oxidative damage and reducing pro-inflammatory events.  
1.4.1.2 ROLE OF 670NM LIGHT IN MITIGATING INFLAMMATION  
Oxidative stress and inflammation are two interrelated processes identified in almost all 
degenerative pathologies of the CNS including Alzheimer’s disease, Parkinson’s disease, 
Leber’s hereditary optic neuropathy (LHON) and AMD. Many studies have shown that 670nm 
light reduces oxidative damage in animal models of methanol-induced retinal toxicity [231], 
rotenone-induced neurotoxicity [255], partial optic nerve transection [222], Parkinson’s 
disease model [255, 256] and Multiple sclerosis animal model [226]. However, there is a lack 
of strong evidence indicating the beneficial effect of 670nm in mitigating inflammation.  
Gene expression analysis in wound-healing studies have shown down-regulation of 
inflammatory factors, such as cytokines and cytokine receptors, following treatment with NIR 
light [214, 257]. While in the light damage-induced degenerating retina 670nm light irradiation 
reduces photoreceptor cell death, activation and recruitment of inflammatory cells, and 
complement propagation [118, 234, 236]. Those studies, however, only investigated changes 
of gene expression, photoreceptor cell function and histology after prolonged recovery periods. 
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Hence, further studies are needed to identify the initiating mechanisms by which 670nm light 
ameliorates the inflammatory processes in retinal degenerations. 
  
1.5 AIMS 
In this thesis I aim to explore the global miRNA expression profile of the rat retina in bright 
light-induced retinal degeneration (Chapter 3), and the role of a particular candidate miRNA 
(miR-124-3p) in the modulation of inflammatory cytokines (Chapter 4). Building on previous 
work conducted in our lab suggesting that 670nm light therapy modulates ncRNAs [96], in 
Chapter 5, I report the impact of 670nm light pre-treatment on the early expression of pro-
inflammatory genes and miRNAs that might modulate inflammation. Conclusions drawn from 
these studies are outlined in Chapter 6.      
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CHAPTER 2: MATERIALS AND 
METHODS 
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2.1 INTRODUCTION 
In Chapters 3-5, experiments were performed to understand the role of miRNA in retinal 
degenerations and developing therapies for treating retinal degenerations. The following 
chapter provides detailed descriptions of all the methodology used in this study. Any additional 
techniques/methods used are mentioned in chapters 3-5.  
 
2.2 ANIMAL REARING AND HOUSING CONDITIONS 
All procedures were performed in accordance with the Association for Research in Vision and 
Ophthalmology (ARVO) statement for use of animals and the Australian National University 
(ANU) ethics protocols outlined by the Animal Experimental Ethics Committee (AEEC). 
Sprague Dawley (SD) albino rats were obtained from the Australian Phenomics Facility (APF) 
and housed at the John Curtin school of Medical Research (JCSMR) animal holding facility. 
Animals were born and raised in dim (5 lux illumination) cyclic light conditions with a 12h 
light, 12h Dark cycle. Food and water was provided in constant supply and cages changed on 
a weekly basis. Animals aged between postnatal day (P) 90-120 were used in light damage 
(LD) experiments. Equal numbers of male and female rats were used throughout the study to 
avoid any gender biases.  
 
2.3 LIGHT DAMAGE EXPERIMENTS 
Adult SD albino rats (P 90 – 120) were placed in individual transparent Perspex chambers and 
exposed to high intensity (1000 lux) bright white light from an overhead fluorescent source for 
24 hours. During the light exposure food was placed on the floor of the chamber and water was 
provided in transparent bottles to avoid barrier to light. 1000 lux light exposure was started at 
9:30AM for all experiments. To encourage increased animal activity during the exposure 
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period, bird seeds and packaging rice puffs were dispersed throughout the Perspex box floor. 
After completion of the 24 hour light exposure period, animals were either sacrificed for tissue 
collection or returned to dim (5 lux) cyclic light conditions to recover for 3 or 7 days. 
 
2.4 LED/NIR 670NM LIGHT TREATMENT 
A WARP 75 (Quantum Devices, WI, USA) light emitting diode (LED) device was used to 
irradiate rat retinas with 670nm light. SD rats were wrapped individually in a cloth and 
positioned under the LED device such that their eyes were approximately 2-3 cm from the light 
source and were maintained in this position for 3 minutes at a 60mW/cm2 output, producing an 
overall energy rate of 9J/cm2 at the eye level. Animals were treated with 670nm light for 3 
minutes once daily, around 9:00AM for 5 consecutive days to account as one complete 
treatment. Sham treated animals were also wrapped individually and maintained in the 
treatment position for 3 minutes daily for 5 days without exposure to 670nm light. 
 
2.5 TISSUE COLLECTION AND FIXATION 
Animals were euthanised by administering an intraperitoneal injection of barbiturate overdose 
(60 mg/kg bodyweight, Valabarb; Virbac, Carros, France). The left eye from each animal was 
extracted for histological analyses while the right eye was used for RNA extraction. For each 
left eye, the superior corneal aspect was marked with a black or red permanent marker prior to 
enucleation using an, forceps and iris scissors. Following enucleation, the eyes were injected 
with freshly prepared 4% paraformaldehyde using a 1ml syringe and 27 gauge needle. The eyes 
were then immersed in 4% paraformaldehyde for 3 hours at 4°C. The retina from the right eye 
of each animal was excised through a corneal incision and placed in RNAlater solution 
(Ambion Biosystems, Austin, TX, USA), stored at 4°C overnight then transferred to -80°C. 
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2.6 HISTOLOGICAL PROCESSING 
2.6.1 CRYOPRESERVATION, EMBEDDING AND SECTIONING 
Following fixation, eyes were rinsed three times with 0.1M PBS for 10 minutes each and 
cryoprotected via overnight immersion in a 30% sucrose solution, made up with 0.1M PBS. 
Eyes were then placed into plastic moulds, with the superior marked side being placed parallel 
to the base of the mould and the cornea facing towards the wall of the mould, filled with Tissue 
Tek Optimal cutting temperature CT mounting medium (Tissue-Tek®, Sakura Finetechnical, 
Japan). The mould was then snap frozen in a solution of isopentane (Sigma Chemical Co., St 
Louis, MI, USA), which was cooled by liquid nitrogen and then placed in -20°C for storage 
(no longer than 1 month). The embedded eyes were cryosectioned using Leica CM1850 
Cryostat at 16µm thickness and mounted directly onto SuperFrost®- Plus slides (Menzel-
Glaser) coated in gelatin (Sigma-Aldrich) and poly-L-lysine (Sigma-Aldrich). Sections were 
cut in the horizontal plane and sections containing the optic nerve head were used in 
experiments in this study to maintain consistency in location within the tissue. Cut sections 
were stored at -20°C until required.  
Alternatively, following 3 hour fixation in 4% paraformaldehyde the anterior chamber 
(including lens) was dissected out and the eyes replaced in 4% paraformaldehyde for 24hrs. 
The eyes were then processed for paraffin coating and embedding before sectioning at 4-6um 
on the microtome, across the superior-inferior axis. Cut sections were stored at 4°C. 
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2.7 HISTOLOGICAL TECHNIQUES 
2.7.1 TUNEL ASSAY 
Cell death was visualised by Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End 
Labeling (TUNEL) assay (Roche Inc, NSW, Australia). TUNEL works by incorporating 
biotinylated UTP to the strand breaks of nicked DNA which is then visualised using 
streptavidin conjugated flurophore. The technique described below is a modified version of the 
technique first described by Gavrieli et al., 1992.  
1. Frozen sections were removed from the -20°C freezer and placed into 70% ethanol for 
15 minutes, followed by two 5 minute washes in dH2O. 
2. Sections were immersed in 1x Tdt buffer (3mM Trizma base, 14mM sodium cacodylate 
and 0.1mM cobalt chloride in dH2O) for 10 minutes.  
3. Sections were then covered in 100-200µl of reaction mixture (1.26 M biotinylated 
dUTP and 0.5 units/µl terminal transferease (TdT) in 1x TdT Buffer) for 1 hour at 37°C 
(Roche). 
4. Reaction was terminated by a 15 minute wash of 2x SSC (0.3M NaCl, 30mM sodium 
citrate). 
5. 10% normal Goat Serum in 1x PBS was then added to the slides to reduce non-specific 
binding of the streptavidin conjugated fluorophore, for 10 minutes. 
6. Slides were then incubated in a 1:200 dilution of Streptavidin Alexa-594 (Vector - 
Invitrogen) in 0.1M PBS for 60 minutes at 37°C, followed by two 5 minute washes in 
0.1M PBS. 
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7. Sections were counterstained with a DNA-specific dye Bisbenzamide (Calbiochem) in 
a 1:10000 dilution for 2 minutes, followed by a final wash in 0.1M PBS for 5 minutes, 
before being coverslipped with Aqua Poly/Mount (Polysciences). 
2.7.2 QUANTITATIVE ANALYSIS OF TUNEL 
The TUNEL+ cells were visualised using a LSM5 confocal fluorescence microscopy (Zeiss) 
and photographed using the Pascal Version 5 software (Zeiss). The TUNEL+ profile counts 
were performed on LSM5 confocal microscope (Zeiss) using Colibri LED system. Cells were 
counted across the full length of the retinal sections cut in the vertical meridian, including at 
the optic nerve head. Cells were counted at 1-mm intervals across retinal sections, the final 
count from each animal was averaged from at least two sections, with four or five animals 
analyzed for each experimental condition. All counts were performed in a masked fashion 
whereby TUNEL labeled slides were de-identified prior to counting.  
2.7.3 TOLUIDINE BLUE STAINING AND RETINAL LAYER THICKNESS 
MEASUREMENT  
Toluidine Blue staining was performed to assess the changes in different layers of the retina.  
1. Sections were dehydrated by immersing in 70% ethanol for 5 minutes. 
2. Slides were rinsed with dH2O for 5 minutes. 
3. Sections were then covered with a few drops of 1% Toluidine Blue and stained for 5 minutes, 
followed by a 5 minute wash in tap H2O.  
4. Sections were then coverslipped in Eukitt®.   
Sections were visualised using transmitted light on the LSM5 confocal microscope (Zeiss), and 
photographed using an Axiocam HRc (Zeiss). Measurements of individual retinal layers were 
obtained using the ProRes® CapturePro 2.5 (JENOPTIK Laser, Optik). Measurements were 
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obtained at the mid-periphery of the superior retina and collected as absolute values expressed 
in micro meters (µm). We took 3 measurements per section, 4 sections per animal and the used 
averaged values for each animal.  
2.7.4 BISBENZAMIDE LABELLING AND ONL THICKNESS MEASUREMENTS  
Bisbenzamide (BBZ), a DNA binding dye, was used to visualise the different cellular layers of 
the retina and used to assess the thickness of the ONL. As mentioned previously, cryosections 
were incubated in BBZ (1:10000; Calbiochem, USA) for 2 minutes, followed by a 5 minute 
wash in 0.1M PBS and coverslipped with Aqua Poly/Mount (Polysciences).  
Sections were visualised using the Leica Axiovert 200 inverted microscope and measurements 
and images obtained using the ProRes® CapturePro 2.5 (JENOPTIK Laser, Optik). At each 
retinal location the thickness of the ONL as well as the retina, from the inner limiting membrane 
to the outer limiting membrane (ILM-OLM) was measured and the ratio of ONL / (ILM-OLM) 
was used to analyse the change in ONL thickness in the different experimental groups. We 
took atleast 8-10 measurements per section each approximately 1mm apart along the retina. A 
minimum of 4 sections per animal were used to perform the measurements and average values 
were plotted for the whole retina.   
2.7.5 IMMUNOHISTOCHEMISTRY 
A listing of antibodies used in this study can be found in table 2.1 and 2.2.  
1. Retinal cryosections were thawed at room temperature for 5 minutes and washed in 
70% alcohol for 10 minutes, followed by a wash in dH20 for 5 mins and two washes 
in 0.1M PBS for 5 minutes each. 
2. A hydrophobic barrier was then drawn around the sections using a Pap-pen 
(ProSciTech, Kirwan, QLD) to prevent the loss of aqueous reagents in the 
subsequent steps. 
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3. Slides were then incubated in 10% normal goat serum for 30 mins to prevent non-
specific binding of the secondary antibody. 
4. Primary antibodies were diluted with 0.1M PBS and 1% serum, to optimal dilutions 
(See table 2.1) and added to the slides, ensuring even coverage. Slides were then 
incubated overnight at 4°C in a humid chamber. 
5. Following the overnight incubation, slides were washed twice in 0.1M PBS for 5 
minutes each. 
6. Secondary antibodies were diluted in 0.1M PBS as detailed in table 2.2, and 
incubated at room temperature for about 2-4 hours.    
7. Slides were then washed three times in 0.1M PBS for 5 minutes each. 
8. Sections were then counterstained using Bizmenzamide incubation (mentioned 
previoulsy), and coverslipped in Aqua Poly/Mount (Polysciences). 
Sections were then visualised using a LSM5 confocal fluorescence (Zeiss), and photographed 
and analysed using Pascal version 4 software (Zeiss). 
2.7.6 MICRORNA IN SITU HYBRIDISATION  
In situ hybridization was performed to localize miRNA expression in the retina using 
commercially available double DIG labelled miR-124-3p miRCURY LNA probe (Exiqon) and 
miRCURY LNA™ microRNA FFPE ISH detection kit 4, according to manufacturer’s 
protocol; Paraffin was stripped off the rat retinal sections using xylene washes and rehydrated 
by washing in a decreasing concentration of ethanol. All retinal sections (Human and Rat) were 
treated with proteinase K (20µg/ml) for 10 minutes. MiR-124-3p probe was hybridized for 1.5 
hours at 53°C and then washed in saline sodium citrate at 58°C. Bound probe was visualized 
with HNPP/Fast-Red (Roche, Basel, Switzerland), which was followed by counter-staining 
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using immunohistochemistry. HNPP/FastRed is a fluorescent substrate for alkaline 
phosphatase that enables sensitive detection of alkaline phosphatase (AP) conjugated 
antibodies. In this study I have used HNPP to detect the AP conjugated anti-DIG antibodies 
bound to the DIG labeled riboprobe hybridized to mature miR-124-3p. HNPP (in combination 
with Fast-red) produces an orange (~562nm) signal post catalysis via AP, which is then 
visualized using fluorescence microscopy. 
1. Slides were deparaffinized by immersing in Xylene for 15 minutes, followed by 
rehydration through washes with decreasing ethanol concentrations: 
100% ethanol (5 minutes) 
100% ethanol (5 minutes) 
90% ethanol (5 minutes)  
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Table 2. 1 
Primary Antibodies used for experiments in this study 
Antibody Source Species Optimal Dilution 
Iba-1 Wako Chemicals Rabbit 1:1000 
Vimentin Abcam Mouse 1:200 
Anti-DIG Sigma Sheep 1:800 
 
 
 
Table 2. 2 
Secondary Antibodies used for immunohistochemistry 
 
Antibody Source Species Optimal Dilution 
Anti-mouse Alexa 488  Invitrogen Goat 1:1000 
Anti-rabbit Alexa 594 Invitrogen Goat 1:1000 
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70% ethanol (5 minutes) 
2. Slides were then washed in 0.1M PBS for 5 minutes and the sections circled with liquid 
blocker – super PAP PEN (Pyramid Innovation) to prevent runoff of solution. 
3. Slides were then incubated with 20ug/ml proteinase-K diluted in 1x Prot-K buffer 
(Prepared according to manufacturer’s protocol) for 10 minutes at 37°C. 
4. Washed in 0.1M PBS twice (5 minutes each). 
5. Slides were then dehydrated by washing with different dilutions of ethanol (freshly 
prepared):    
70% ethanol (1 minute) 
90% ethanol (1 minute) 
100% ethanol (1 minute) 
6. Thereafter, the slides were air dried for approximately 15 minutes inside a class II 
biosafety cabinet. While the hybridization probes were prepared to required 
concentrations by heat shocking at 90°C for 4 minutes, followed by diluting in 1x 
hybridization buffer equilibrated to the hybridization temperature of the ISH probes. 
7. 100-140µl of the probe-hyb buffer mix was then applied to the slides, coverslipped and 
hybridized at 53 °C for 1.5 hours. 
8. After the incubation period the coverslip was removed and the slides washed in 
different grades of Saline Sodium Citrate (SSC) buffer maintained at 4-5°C above the 
hybridization temperature.  
5x SSC (1 minute) 
1x SSC (5 minutes) 
1x SSC (5 minutes) 
0.2x SSC (5 minutes) 
0.2x SSC (5 minutes) 
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9. Slides were then washed in 0.1M PBS for 5 minutes. And incubated with blocking 
solution (including 2% Sheep serum and 1% Bovine serum albumin BSA) for 15 
minutes at room temperature in a humid chamber. 
10. Following blocking, slides were incubated with sheep-anti-DIG antibody (refer table 
2.1) diluted in 0.1% PBS-T (including 1% Sheep serum and 1% BSA) at a 1:800 
dilution for 2x 30 minutes (Room temperature). 
11. Slides were then washed three times in 0.1% PBS-T for 3 minutes each. 
12. Washed in 1x Detection buffer (containing Magnesium ions) for 5 minutes. 
13. And incubated with a freshly prepared fluorescent AP substrate (Fast Red) at room 
temperature until the stain developed.  
14. Sections were then double labelled with specific antibodies by following the protocol 
described in section 2.7.5 and coverslipped with Aqua Poly/Mount (Polyscience). 
 
2.8 RNA ISOLATION AND ANALYSES  
2.8.1 RNA EXTRACTION 
RNA isolation was performed using TRIzol reagent (Invitrogen) in conjunction with 
RNAqueous® kit (Ambion) for rat retina or RNAqueous®-Micro kit (Ambion) for cells. After 
animals were sacrificed, the retina was dissected out of the eye cup and placed in 1.5ml tube 
containing 200µl TRIzol. Retinas were homogenised on ice followed by addition of another 
400µl TRIzol and 120µl chloroform, vortexed for 20secs and allowed to sit at room 
temperature for 7 minutes. The tubes were then centrifuged at 13,000g for 10 minutes at 4 °C. 
The clear supernatant was then carefully removed and placed in a clean 1.5ml tube along with 
half its volume in 100% ethanol. Following this the tube was vortexed briefly before 
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commencing the purification and elution steps outlined in Part C of the RNA Isolation protocol 
provided with the kits (Ambion). 
For in vitro work, 500µl TRIzol was used to detach and harvest cells from the culture plates 
followed by addition of 120µl chloroform. Remaining steps were similar to those outlined 
above and the purification and elution steps were as mentioned in the RNAqueous-Micro kit 
protocol (Ambion).   
2.8.2 RNA ANALYSIS 
Purified RNA was quantified on a ND-1000 (Nanodrop Technologies, Wilmington, DE) 
spectrophotometer. While, the 2100-Bioanalyser (Agilent Technologies, Santa Clara, CA, 
USA) was used to identified the purity and quality of RNA. Only RNA samples with a 
A260/A280 ratio above 1.8 and an RNA integrity number (RIN) greater than 8.0 were used for 
the study. The RNA samples were stored at -80 °C before performing further analyses. 
 
2.9 CDNA SYNTHESIS  
Complementary DNA (cDNA) was prepared using the TaqMan® MicroRNA Reverse 
Transcription kit (Applied Biosystems) – for miRNAs and the Tetro cDNA synthesis kit 
(Bioline) – for mRNAs, following manufacturer’s directions as detailed below: 
2.9.1 TAQMAN® MICRORNA RT KIT (MIRNA) 
1. Purified RNA was primed in a sterile 0.2ml tube by mixing 0.5-1µg RNA with RNase 
free H2O up to a total volume of 5µl. 
2. The RNA mix was then incubated at 65°C for 5 minutes and placed on ice for 5 minutes. 
3. Samples were centrifuged and added to 7µl of the reverse transcription mix containing 
1.5µl 10x RT buffer, 0.15µl dNTP mix, 0.19 µl RNase off (20 U/µl), 1µl Multiscribe™ 
RTase (50 U).  
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4. Then 3µl of specific miRNA RT primer pool was added to the tubes and mixed by 
vortexing.  
5. The combined 15ul reaction mix was then placed into the VERITI® PCR machine 
(Applied Biosystems) and run with the following cycling program: 16°C for 30minutes; 
42°C for 30minutes and 85°C for 5 minutes. Followed by hold at 4°C.  
6. The resulting cDNA was then used for real time qPCR or stored at -20°C. 
      
2.9.2 TETRO CDNA SYNTHESIS KIT (MRNA) 
1. Purified RNA was primed in a sterile 0.2ml tube by mixing 1µg RNA with 1µl Oligo 
(dT)18 primers (500µg/ml), 1µl dNTPs (10mM), made up to 14µl with RNase free 
H2O. 
2. This mix was incubated at 70°C for 5 minutes and placed on ice for 5 minutes. 
3. Samples were then centrifuged and added to 6ul of reverse transcription mix containing 
200 U Tetro Reverse Transcriptase, 4 µl 5x RT buffer and 10U Ribosafe RNase 
Inhibitor.         
4. The tubes were then mixed by vortexing and the 20µl reaction mixture centrifuged 
before placing into the VERITI® PCR machine (Applied Biosystems).  
5. The cycling program was run as follows: 30 minutes at 45°C for the reaction to occur, 
followed by 5 minutes at 85°C to terminate reaction and hold at 4°C.  
6. The resulting cDNA was then used for real time qPCR or stored at -20°C. 
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2.10 QUANTITATIVE REAL TIME POLYMERASE CHAIN 
REACTION (QRT-PCR) 
Changes in expression of genes of interest (both miRNA and mRNA) were determined by qRT-
PCR using TaqMan® hydrolysis probes (Applied Biosystems) and Gene Expression 
Mastermix (Applied Biosystems). All the TaqMan probes used are listed in table 2.3. qPCR 
was performed on the QuanStudio™ 12K Flex Real-Time PCR System (Applied Biosystems) 
and results analysed using the QuantStudio 12K Flex Software (Applied Biosystems).  
For each comparison, every gene was run as a technical duplicate across a biological triplicate 
to account for individual sample and animal variability. A 10µl final reaction volume was used 
in a 384 well clear PCR plate, setup as follows: 
1. 0.5-0.9 µl cDNA was added to RNase free water to achieve 4.5µl total volume. 
2. This solution was added to 5µl TaqMAn gene expression master mix (Applied 
Biosystems) and 0.5ul TaqMan primer probe assay. 
3. The following program was then run on the QuantStudio 12K Flex qPCR machine: 
Step Temperature (°C) Duration Cycles 
UDG Incubation 50 2 minutes 1x 
AmpliTaq Gold, UP 
Enzyme activation 
95 10 minutes 1x 
Denature 95 15 seconds Cycle 40x 
Anneal and Extend* 60 1 minute                    
*fluorescence level is measured automatically at the end of each cycle, to establish the 
critical threshold cycle.  
        
2.10.1 QPCR ANALYSIS 
Fold change was determined using the comparative delta-delta Ct method. The QuantStudio 
12K Flex Software performs the calculations using the Critical threshold cycle obtained (Ct) 
and the following equation: 
Normalised Target Gene expression level = 2(-ΔΔCt)  
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Where, ΔCt = Ct (Target Gene) – Ct (Endogenous control Gene)     
ΔΔCt = ΔCt (Experimental sample) – ΔCt (Control sample) 
In this study the reference gene used for the mRNA quantification was GAPDH, while U6 was 
used as the reference gene for miRNA quantification. All qPCRs in this study were performed 
and reported in accordance with the Minimum Information for Publication of Quantitative 
Real-Time PCR Experiments (MIQE) guidelines. 
 
2.11 MICRORNA LOW DENSITY ARRAY 
The RNA from dim-reared control retinas, 24-hour light exposed retinas and 670nm treated 
dim-reared retinas were used for miRNA array card analysis. Total RNA (700 ng) from each 
animal was reverse transcribed to two different cDNA pools (each containing 350 ng of 
miRNAspecific cDNA) using the Megaplex RT Primers, Rodent Pool A and B Set v3.0 
(Applied Biosystems, Carlsbad, CA, USA) and TaqMan miRNA RT kit (Applied Biosystems) 
according to manufacturer’s protocol; a 7.5µL reaction mixture, including 50 U Multiscribe 
Reverse Transcriptase and 20 U RNase inhibitor. Card A contains well characterized miRNAs 
in miRBase v16.0 (available in the public domain at www.mirbase.org), while B contains 
uncharacterized ones. Both A and B samples then were hybridized to the respective TaqMan 
Array Rodent MicroRNA Cards v3.0 (A and B), which are preconfigured microfluidic 384-
well format plates. Each well in the microfluidic card consists of a TaqMan chemistry-based 
primer probe set for a unique miRNA or other RNA (control sequences). A total of 20 
microRNA cards were run (10 A cards and 10 B cards). The microfluidic cards then were run 
on the ViiA 7 Real-time PCR machine (Applied Biosystems) to generate the raw expression 
data. The expression data were compiled and exported into an excel format using the 
Expression Suite Software. And analyzed using PARTEK Genomic Suite 6.6 software (Partek, 
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Inc., St. Louis, MO, USA). Amplification data for the target miRNAs were first normalized by 
subtracting the endogenous control (Y1) values.   
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TaqMan® Hydrolysis probes used 
 
 
  
Table 2. 3 
Gene/miRNA 
Symbol 
Name Accession # Catalog # 
Ccl2 Chemokine (C-C motif) ligand 2 NM_031530.1 Rn01456716_g1 
Ccl3 Chemokine (C-C motif) ligand 3 NM_013025.2 Rn00564660_m1 
Ccl4 Chemokine (C-C motif) ligand 4 NM_053858.1 Rn00587826_m1 
Ccl7 Chemokine (C-C motif) ligand 7 NM_01007612.1 Rn01467286_m1 
CxCL1 Chemokine (C-X-C motif) ligand 1 NM_030845.1 Rn00578225_m1 
CxCL10 Chemokine (C-X-C motif) ligand 10 NM_139089.1 Rn01413889_g1 
CxCL11 Chemokine (C-X-C motif) ligand 11 NM_182952.2 Rn00788262_g1 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
NM_017008.3 Rn99999916_s1 
IL1β Interleukin 1β NM_031512.2 Rn00580432_m1 
miR-351 mmu-miR-351 MIMAT0000609  001067 
miR-155 mmu-miR-155 MIMAT0000165  002571 
miR-124-3p mmu-miR-124-3p MIMAT0000422 001182 
miR-183 has-miR-183 MIMAT0000860  002269 
U6 U6 small nuclear RNA NR_004394 001973 
miR-125b-3p hsa-miR-125b-3p MIMAT0004592 002378 
miR-542-3p mmu-miR-542-3p MIMAT0003172 001284 
miR-449a hsa-miR-449a MIMAT0001541 001030 
miR-347 rno-miR-347  MIMAT0000598 001334 
miR-207 mmu-miR-207 MIMAT0000240 001198 
miR-182 mmu-miR-182 MIMAT0005300 002599 
miR-96 mmu-miR-96 MIMAT0000818 000186 
miR-467d mmu-miR-467d MIMAT0004886 002518 
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Differential expression was examined using the 1-way ANOVA statistic with a significance 
cutoff of P < 0.05. The statistical robustness of the expression data was visualized with 
principle component analysis (PCA), provided within the Partek Genomic Suite 6.6 software. 
MicroRNA expression distribution was visualized using the volcano plot tool embedded within 
the Partek software. A list of significantly regulated miRNAs was generated from the volcano 
plot by selecting for miRNAs that changed ‡2-fold and had a P value of <0.05. These highly 
modulated miRNAs were used for biological functional analyses using PARTEK Genomic 
Suite 6.6. 
 
2.12 IN-VITRO STUDIES 
2.12.1 CELL REARING AND STIMULATION 
Cell culture experiments were performed using HeLa cells and low passage (<10) immortalized 
human Müller cell line (MIO-M1). We also used low passage number 661W photoreceptor cell 
line, generously provided by Dr. Muayyad Al-Ubaidi (University of Oklahoma), and an 
immortalized RPE cell line (ARPE19) for this study. Cells were used within 10 passages of 
authentication and validation from Cell Bank Australia. And were further validated using RT-
PCR for expression of cell specific markers including SW opsin, M opsin pigments, SV40 for 
661W cells; RPE65, RLBP1 for ARPE19 cells; GFAP, Vimentin for MIO-M1 cells. Cells were 
cultured in Dulbeco’s Modified Eagle’s Medium (DMEM; Invitrogen) containing 10% fetal 
bovine serum, L-glutamine (3 mM), sodium pyruvate (1 mM) and glucose (25 mM) and stored 
in an incubator at 37°C, 5% CO2. Human IL-1β protein (10ng/ml) was used as a pro-
inflammatory stimulus for MIO-M1 and ARPE19 cell lines. While, 661W photoreceptor cells 
were stimulated by bright light induced damage. The cell culture plate, containing 80-90% 
confluent cells, was placed under 15,000 lux light for 5 hours while inside an incubator 
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maintained at 37°C and 5% CO2 to ensure even distribution across the plate. The temperature 
of the setup was monitored vigilantly using a thermometer placed next to the culture plate. 
2.12.2 MIO-M1 CELL TRANSFECTION AND STIMULATION  
MIO-M1 cells were seeded in clear plastic 6-well tissue culture plates at a density of 80,000 
cells per well and the medium was replaced with 2.5 ml low serum (1%) growth medium after 
sufficient adhering time (24 hours). Cells were then incubated at 37 °C, 5% CO2 for 12h and 
transfected with miR-124-3p mimic (UAAGGCACGCGGUGAAUGCC) or miR-124a 
inhibitor (GGCAUUCACCGCGUGCCUUA) or negative control miRNA mimic (Ambion) 
using Lipofectamine RNAiMAX (Invitrogen) as follows:  
1.5µl miRNA stock (10µM) was combined with 300µl Opti-MEM® and 9µl Lipofectamine 
RNAiMAX®. Vortexed and incubated for 5 minutes at room temperature. Then 250µl of the 
miRNA:Lipofectamine complex was added to each well, and the plate returned to the 
incubator.  
24hrs post transfection cells were exposed to 10ng/ml IL-1β protein for a duration of 12hrs. 
The cells were then harvested using TRIzol (Invitrogen) reagent and RNA extracted using the 
RNAqueous-Micro RNA Isolation Kit (Ambion, Applied Biosystems) [refer section 2.8.1]. 
2.12.3 LUCIFERASE ASSAY 
Luciferase assay is used to establish the direct binding between miRNA and their respective 
target 3’UTRs. In this study it was performed in both HeLa and MIO-M1 cells using a 
commercially available vector containing the renilla luciferase gene fused to the human CCL2 
3’UTR (CCL2 LightSwitch 3’UTR Reporter GoClone; Switchgear Genomics, CA, USA) and 
the pLightSwitch-3’UTR Luciferase assay system (Switchgear Genomics, CA, USA), 
following the manufacturer’s protocol. Cells were seeded into a white 96 well plate (5000 cells 
per well) and cultured for 24hrs, similar to cell rearing conditions, in 100µl 10% growth 
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medium. Once they reached ~90% confluence, the growth media was replaced with fresh media 
and the cells were transfected with either the vector only or co-transfected with the vector and 
miR-124-3p mimic (Ambion) or co-transfected with the vector and negative control miRNA 
mimic (Ambion) following the below mentioned protocol: 
1. miRNA mimics and inhibitors were transfected into cells using Lipofectamine® 
RNAiMAX transfection reagent (Life Technologies). 1µl miRNA mimic or inhibitor 
stock (10 µM) was added to 50µl Opti-MEM® and 1.5 µl RNAiMAX reagent, mixed 
by vortexing and incubated at room temperature for 5 minutes.  
2. Then 10ul of the miRNA:Lipofectamine complex was added to each well containing 
100µl 10% growth medium, resulting in a final miRNA mimic/inhibitor concentration 
of 20nM in each well. 
3. CCL2 3’UTR GoCLone was transfected into the cells simultaneously using ViaFect™ 
transfection reagent (Promega). 3.33µl of the GoClone stock (30ng/µl) was combined 
with 0.6µl ViaFect™ and 6.07µl Opti-MEM® medium, mixed by vortexing and 
incubated at room temperature for 15 minutes. 
4. Thereafter, 10µl of Plasmid Vector:ViaFect™ complex was added to each well.  
5. The plate was then returned to the incubator for 48 hours before testing for luciferase 
activity.   
Müller cells were transfected with the CCL2 3’UTR GoClone only and placed in the incubator 
for 36 hours before stimulation with IL1β protein (10ng/ml) for a period of 12 hours.  
The luciferase activity for both HeLa and MIO-M1 cells was then analysed using the 
LightSwitch® Luciferase assay system (SwitchGear Genomics), which was performed 
according to manufacturer’s protocol mentioned in the following document: 
https://www.activemotif.com/documents/1946.pdf. 
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And the luciferase assay reagent bioluminescence was measured by Infinity® 200 plate reader 
(TECAN, Austria). Statistics were performed using Student’s t-test. 
STATISTICAL ANALYSES 
Varying combinations of different statistical tests were used throughout the thesis to perform 
statistical analyses of the data presented. Majority of the data were analysed using GraphPad 
PRISM® statistical software (v5.0, GraphPad Software Inc., San Diego, CA, USA). Parametric 
One and Two way ANOVA tests along with tukey’s and Bonferroni post hoc tests were used 
for data analyses. In most cases Student’s t-tests were also employed on the data to confirm 
statistical significance. Results are presented as mean values with standard error of the mean 
(SEM) as error bars. P value of <0.05 was considered significant.   
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CHAPTER 3: IDENTIFICATION OF 
MIRNAS IN A MODEL OF RETINAL 
DEGENERATIONS  
 
 
This chapter is a reproduction of previously published work: 
Saxena K, Rutar MV, Provis JM, Natoli RC. (2015) “Identification of miRNAs in a Model of 
Retinal Degenerations.” Invest Ophthalmol Vis Sci. Feb 24;56(3):1820-9. 
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3.1 INTRODUCTION 
MicroRNAs (miRNAs) are small evolutionarily conserved non-coding RNA sequences that 
modulate a range of biological processes [129] including cell death [258, 259] and 
inflammation [260]. They are ~22-25 nucleotides long and provide a second layer of post-
transcriptional gene regulation by targeting messenger RNAs (mRNAs) for degradation or 
repression of translation [163], and are found in abundance in the CNS [165, 261].  
Age-related macular Degeneration (AMD) is a progressive degenerative disease of the retina 
that causes irreversible vision loss and accounts for up to 50% of central blindness cases 
worldwide. The involvement of inflammatory processes in the pathogenesis of AMD was 
documented in the 1980s [63] with gene association studies providing strong statistical support 
for its involvement in disease pathogenesis [2, 3, 262]. Subsequently a large number of 
inflammatory factors and co-factors, particularly in the complement pathways, have been 
implicated in the disease process (for a review see [263]).  
The acute retinal light damage (LD) model in rats has features in common with dry AMD [105, 
113], including cell death and inflammation [105]. This model has been used to investigate the 
involvement of chemokines and macrophages in the progression of retinal degeneration [98]. 
Following light damage (LD) a lesion formed by the death of photoreceptors and atrophy of 
the RPE presents on the visual axis and enlarges over time, even in the absence of the damaging 
stimulus [105]. In this model photoreceptor death is associated with expression of chemokines 
by Müller glia, recruitment of macrophages and deposition of C3 [119], and attenuation of 
macrophage recruitment, by silencing expression of the chemokine CCL2, reduces 
photoreceptor cell death [97]. Similar patterns of chemokine expression, macrophage 
recruitment, C3 deposition and photoreceptor cell death are present in the normally aging rat 
[264], indicating that the model represents many of the features of normal aging of the retina. 
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Recent evidence supports the idea that miRNA are involved in inflammation [265, 266]. Many 
miRNAs are rapidly upregulated in response to inflammatory cues and may either promote the 
duration and magnitude of inflammation [267] or silence it [176]. In this study we investigated 
the modulation of miRNAs in the rat LD model of focal retinal degeneration and explored the 
transcriptional profile of their target genes in the retina following LD, with a focus on 
identifying miRNA that modulate expression of genes involved in the inflammatory response. 
  
3.2 METHODS 
3.2.1 ANIMALS AND LIGHT DAMAGE 
Animal handling and treatment protocols were carried out in accordance with the ARVO 
statement describing the ethical use of animals in vision research, and were approved by the 
ANU Animal Ethics Committee. Sprague Dawley (SD) rats aged 90-140 post-natal days raised 
in dim (5 lux) cyclic light (‘dim-reared’) were used for the study. Light damage was induced 
by exposure to bright light (1000 lux) from an overhead white fluorescent source (COLDF2 
2x36W IHF, THORN lighting, Australia) for a period of 24 hours. Food was provided ad 
libitum. At the end of the exposure period animals were either euthanized immediately by 
intraperitoneal injection of barbiturate overdose (60mg/kg bodyweight, Valabarb; Virbac), or 
were returned to dim light (5 lux) conditions for 3 or 7 days prior to euthanasia. Retinal tissue 
was collected immediately for analysis. Age-matched, dim-reared animals were used as 
controls. All experimental groups were n=5, unless otherwise stated.   
3.2.2 TISSUE COLLECTION 
The retina from the right eye of each animal was excised through a corneal incision and placed 
in RNAlater solution (Ambion Biosystems, Austin, TX), stored at 4°C overnight then 
transferred to -80°C. The left eye from each animal was enucleated, the superior margin 
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marked, then immersed in 4% paraformaldehyde for 3h at 4°C. The anterior segment was 
removed then the eye cups replaced in fresh 4% paraformaldehyde overnight at 4°C, and 
subsequently prepared for paraffin embedding. Eyes were sectioned at 6 µm on a microtome 
on the vertical axis. Only sections containing the optic nerve were used for analysis. 
3.2.3 RNA EXTRACTED FROM RAT RETINA 
Total RNA was extracted from retinal samples using the mirVana miRNA isolation kit 
(Ambion, Austin, TX), according to manufacturer’s protocol. The concentration of the RNA 
was determined by ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE) 
and quality using the 2100-Bioanalyser (Agilent Technologies, Santa Clara, CA). Only RNA 
samples with a A260/A280 ratio above 1.9 and a RNA integrity number (RIN) greater than 8.0 
were used for the study. RNA samples were stored at -80°C before performing Taqman miRNA 
array studies.    
3.2.4 TAQMAN MIRNA ARRAY AND ANALYSIS  
RNA from dim-reared control retinas and 24hr light-exposed retinas were used for miRNA 
array card analysis. 700ng of total RNA from each animal was reverse transcribed to two 
different cDNA pools (each containing 350ng of miRNAs-specific cDNA) using the 
Megaplex™ RT Primers, Rodent Pool A and B Set v3.0 (Applied Biosystems) and TaqMan 
miRNA RT kit (Applied Biosystems) according to manufacturer’s protocol; a 7.5µl reaction 
mixture including 50U Multiscribe™ Reverse Transcriptase and 20U RNase inhibitor. Card A, 
contains well characterized miRNAs in miRBase v16.0 (www.mirbase.org), while B contains 
uncharacterized ones. Both A and B samples were then hybridized to the respective TaqMan® 
Array Rodent MicroRNA Cards v3.0 (A and B), which are pre-configured microfluidic 384 
well format plates. Each well in the microfluidic card consists of TaqMan® chemistry based 
primer probe set for a unique miRNA or other RNA (control sequences). 20 microRNA cards 
were run in total (10 A cards and 10 B cards). The microfluidic cards were then run on the 
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ViiA™ 7 Real-time PCR machine (Applied Biosystems) to generate the raw expression data. 
The expression data was compiled and analysed using PARTEK® Genomic Suite™ 6.6 
software (Partek Inc., St.Louis, MO, USA). Amplification data for the target miRNAs was first 
normalized by subtracting the endogenous control (Y1) values. Differential expression was 
examined using the 1way-ANOVA statistic with a significance cutoff of p<0.05. The statistical 
robustness of the expression data was visualized with principle component analysis (PCA), 
provided within the Partek® Genomic Suite™ 6.6 software. MicroRNA expression 
distribution was visualized using the volcano plot tool embedded within the Partek® software. 
A list of significantly regulated miRNAs was generated from the volcano plot by selecting for 
miRNAs that changed ≥ 2-fold and had a p-value<0.05. These highly modulated miRNAs were 
used for biological functional analyses using PARTEK® Genomic Suite™ 6.6. 
3.2.5 BIOLOGIC FUNCTIONAL ANALYSES 
We used data from a previous microarray analysis [96] (accessible through gene expression 
omnibus (GEO) Series accession number GSE22818) identifying genes modulated by light 
damage in this same LD model, to identify potential target genes for our differentially 
expressed miRNAs. To achieve this, the relevant gene expression microarray data (and their 
accompanying Affymetrix CEL files) was imported into PARTEK® Genomic Suite™ 6.6 
software (Partek Inc., St.Louis, MO, USA) along with the current miRNA expression data to 
compare the two expression profiles. Predicted gene targets were determined using the 
TargetScan v6.2 algorithm via the PARTEK® software. Which were then subjected to 
functional analysis via Gene Ontology (GO) enrichment within PARTEK® and clustered 
according to their respective biological processes.
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Table 3. 1 
Taqman® small RNA probes used 
miRNA ID Accession # Product Number 
mmu-miR-155 MIMAT0000165 002571 
hsa-miR-125b-3p MIMAT0004592 002378 
mmu-miR-351 MIMAT0000609 001067 
mmu-miR-542-3p MIMAT0003172 001284 
hsa-miR-449a MIMAT0001541 001030 
rno-miR-347  MIMAT0000598 001334 
mmu-miR-207 MIMAT0000240 001198 
U6 snRNA NR_004394 001973 
mmu-miR-182 MIMAT0005300 002599 
hsa-miR-183 MIMAT0000860 002269 
mmu-miR-96 MIMAT0000818 000186 
mmu-miR-467d MIMAT0004886 002518 
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3.2.6 QUANTITATIVE REAL-TIME PCR 
cDNA was synthesized using the TaqMan® MicroRNA RT kit (Applied Biosystems, Life 
technologies) according to manufacturer’s protocol; a 15µl reaction mixture including 500ng-
1µg RNA, 50U Multiscribe™ Reverse transcriptase, 3µl 5X miRNA specific RT primer and 
3.8U RNase Inhibitor. MiRNA amplification was measured using commercially available 
miRNA specific TaqMan® hydrolysis probes (Applied Biosystems) detailed in Table 3.1. The 
hydrolysis probes were utilized according to the manufacturer’s directions in a 10µl reaction 
mix along with TaqMan® Gene Expression Mastermix and the cDNA. Fluorescence was 
measured by the FAM 510nm channel in the 7900HT Real-time PCR machine (Applied 
Biosystems), ROX™ passive reference dye present in the Gene Expression Mastermix was 
used to normalise samples in individual wells. Each biological sample was amplified in a 
technical replicate and the average Ct (Critical threshold cycle) value was used to determine 
the change in expression. Fold change was calculated using the ΔΔCt method where target 
miRNAs were normalized to the expression of small nuclear RNA U6 (reference RNA), which 
showed no differential expression in this study. Gel electrophoresis was used to access 
amplification specificity and statistical analysis was performed using 1-way ANOVA and 
Student t test, using Prism (GraphPad Software V5). 
3.2.7 ANALYSIS OF CELL DEATH 
TdT-mediated dUTP nick end labeling (TUNEL) technique was used to quantify cell death 
over the LD timecourse, in retinal cryosections using a previously published protocol[96]. 
TUNEL positive cells in the outer nuclear layer (ONL) were counted across the full length of 
the retinal sections cut in the vertical meridian, including at the optic nerve head. Cells were 
counted at 1mm intervals across retinal sections, the final count from each animal was averaged 
from at least two sections, with four or five animals analysed for each experimental condition. 
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Statistical analysis was performed using 1-way ANOVA and Student t test, using Prism 
(GraphPad Software v5). 
 
3.3 RESULTS 
3.3.1 TUNEL ANALYSIS 
There was an evident increase in the number of photoreceptor cells undergoing apoptosis 
following exposure to 24hrs bright light, consistent with our previous reports (Figure 3.1). This 
increase was more prominent in the superior retina approximately 2mm superior temporal to 
the optic disc, shown in the representative image panels (Figure 3.1A-D). We observed a peak 
in the number of TUNEL+ cells in the ONL after 24hrs bright light exposure followed by a 
significant decrease during the post exposure periods, 3 and 7 days, as well as a progressive 
thinning of the ONL/photoreceptor layer as described previously [98]. 
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Figure 3. 1 Photoreceptor cell death across protracted LD timecourse 
The number of TUNEL positive photoreceptor nuclei in the ONL was used to estimate 
progression of retinal degeneration at 3 time points. Representative TUNEL staining images 
are documented in A-D, while total number of TUNEL positive cells (across the entire retinas) 
is quantified in E. n=5; error bars represent SEM. 
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3.3.2 MICRORNA PROFILING 
The PCA plot (Figure 3.2) shows that the biological replicates are clustered close together and 
that majority of variation between the Control and LD groups (50.3%) is due to LD, rather than 
inherent variability within the groups. The volcano plot (Figure 3.3) shows that a large number 
of miRNAs were modulated up or down by LD. A list of candidate miRNAs (Table 3.2) was 
compiled by selecting those with a fold-change ≥ 2 or ≤ -2, and p<0.05. A total of 37 miRNAs 
of the 750 tested showed strong statistical significance and were selected for further analysis. 
The most highly upregulated miRNA was mmu-miR-467d (66 fold) while mmu-miR-
1224_mat was the most downregulated (-16 fold). Of the 37 miRNAs, 26 were upregulated 
and 11 downregulated; 17 came from the miRNA array card A, which represents the better 
characterized miRNAs in miRBase v16.0 (www.mirbase.org), while 20 were from the not-so-
well-characterized group on array card B.  
3.3.3 FUNCTIONAL ANALYSIS OF MIRNAS  
Each miRNA targets multiple mRNAs, therefore the list of predicted gene targets is much 
larger than the list of significantly regulated miRNAs. The list of gene targets (from the ~2000 
genes analysed) of the 37 miRNAs were analysed using PARTEK®, to gain insight into their 
biological relevance by Gene Ontology (GO) enrichment clustering based on ‘biological 
processes’. Through this process we identified the 10 most highly represented gene ontology 
clusters (Table 3.3). The ‘biological processes’ with the highest enrichment scores include 
positive regulation of cell proliferation (22.5502), inflammatory response (19.9534), positive 
regulation of transcription from RNA polymerase II promoter (19.7899), and angiogenesis 
(19.3955). Table 3.4 shows the 19 miRNAs associated with ‘inflammatory response’ and 
identifies the 30 gene targets of those miRNAs. Functional clustering of those genes using the 
DAVID® Bioinformatics annotation tool 6.7 identifies 7 out of 30 genes clustering into two 
families of chemokines; the CCL (3,4,7 and 12) and CXCL (1, 10 and 11) families.  
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3-D Principle Component Analysis. Each sphere represents a sample and the circle represents 
the centroid of each distribution. Samples from animals not exposed to LD (red) are more 
tightly clustered than samples from LD animals (blue), indicating less variability in miRNA 
expression profiles in control animals compared to animals exposed to LD. The majority of the 
variance between the 2 different conditions is explained by the PC-1 axis.  
  
Figure 3. 2 Principle component analysis (PCA) plot 
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Table 3. 2 
Candidate microRNAs 
miRNA ID p-value Fold-Change F Statistic 
mmu-miR-467d 0.00537844 66.934 9.22 
mmu-miR-155 0.00502399 55.9242 6.03 
mmu-miR-466h 0.0395309 49.8464 2.27 
mmu-miR-220 0.0149566 30.91 3.98 
mmu-miR-125b-3p 0.0231669 17.3396 2.55 
mmu-miR-207 0.00461902 13.4394 5.00 
mmu-miR-449a 0.00346565 10.2821 4.97 
mmu-miR-467c 0.0121979 9.33694 3.50 
mmu-miR-291-5p 0.0149867 7.41014 2.67 
mmu-miR-542-3p 0.00820295 7.16889 4.77 
mmu-miR-715 0.00948857 6.65874 3.28 
rno-miR-347 0.0431166 5.4159 2.71 
mmu-miR-494 0.0108949 5.20176 3.94 
mmu-miR-351 0.00859523 4.86756 3.45 
mmu-miR-1894-3p_mat 0.0145028 4.48047 3.78 
mmu-miR-582-3p 0.0339127 4.4609 8.80 
hsa-miR-223 0.00343764 4.34528 6.58 
mmu-miR-685 0.00584433 4.03733 6.29 
mmu-miR-1971_mat 0.000432933 3.9048 8.13 
mmu-miR-300 0.0460522 3.78183 3.94 
mmu-miR-1195 0.0273212 3.43057 2.89 
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mmu-miR-2183_mat 0.000281241 3.15076 13.05 
mmu-miR-509-3p 0.0192239 2.9015 2.50 
mmu-miR-335-3p 0.00999525 2.76217 5.50 
hsa-miR-214 0.0291568 2.42738 2.23 
mmu-miR-466k_mat 0.0278496 2.2071 3.32 
mmu-miR-720 0.0108249 -2.22245 3.07 
mmu-miR-376b# 0.00855768 -2.41404 3.27 
hsa-miR-124# 0.0217727 -3.01279 2.69 
hsa-miR-411# 0.00789667 -3.08945 3.39 
mmu-miR-337 0.00319273 -3.23811 4.88 
mmu-miR-466d-5p 0.00911546 -3.27501 425.18 
rno-miR-743a 0.0272182 -3.56685 2.28 
mmu-miR-1939_mat 0.0208102 -5.05438 3.73 
mmu-miR-1306_mat 0.012169 -7.46789 2.87 
mmu-miR-742 0.00173378 -12.9825 22.07 
mmu-miR-1224_mat 0.0184421 -16.0222 19.46 
*  ‘–‘ in front of the Fold-Change value indicates a downregulation  
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Figure 3. 3 Volcano plot representation of miRNA expression profile 
Volcano plot of miRNA expression levels against probability. Only data points lying above the 
dotted line are significant (p≤0.05). The solid vertical line indicates zero change in gene 
expression. Points to the right (green) represent candidates that were up-regulated by LD, while 
points to the left (red) were down-regulated. 
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Table 3. 3 
Highly represented clusters of biological functions  
modulated by candidate microRNAs 
Biological Process Enrichment 
Score 
Enrichment p-
value 
Gene Ontology 
ID 
Positive regulation of cell proliferation 22.5502 1.61E-10 GO: 8284 
Inflammatory response 19.9534 2.16E-09 GO: 6954 
Positive regulation of transcription 
from RNA polymerase II promoter 
19.7899 2.54E-09 GO: 45944 
Angiogenesis 19.3955 3.77E-09 GO: 1525 
Negative regulation of cell proliferation 17.4925 2.53E-08 GO: 8285 
Cell adhesion 16.9623 4.30E-08 GO: 7155 
Cell-cell adhesion 16.9308 4.44E-08 GO: 16337 
Negative regulation of transcription, 
DNA-dependent 
16.8136 4.99E-08 GO: 45892 
Transcription, DNA-dependent 16.5114 6.75E-08 GO: 6351 
Transport 16.0281 1.09E-07 GO: 6810 
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3.3.4 TEMPORAL EXPRESSION OF INFLAMMATION-ASSOCIATED MIRNAS 
Based on the expression signal-to-noise ratio (Critical F value = 2.55), consistency across 
biological replicates, we selected 8 miRNAs involved in regulating inflammatory responses for 
validation by qPCR. We tested the expression levels of miR-125-3p, miR-155, miR-207, miR-
351, miR-449a, miR-542-3p, miR-467d and rno-miR-347 at three time points - 24hrs light 
exposure, 3 and 7 days post-exposure (Figure 3.4 A-C). In addition to these, we verified the 
expression pattern of microRNA cluster miR-183/96/182 at the three timepoints (Figure 3.4D), 
which has previously been shown to express selectively in photoreceptors, is modulated in 
rodent models of retinal degenerations and due to environmental light conditions.  
Two different expression patterns of the miRNA subset were detected across the time points. 
Five miRNAs (miR-207, -347, -125b-3p, -155 and -449a) reached peak expression at 3d post 
exposure (Figure 3.4 B, C); in contrast, two miRNAs, (miR-542-3p and -351) were 
continuously upregulated over the timecouse (Figure 3.4A). We were unable to generate 
consistent fold change values for miR-467d across the biological replicates due to very high 
(end stage) Ct cycle numbers.  
MicroRNA cluster miR-183/96/182 exhibited a downward expression trend across the LD time 
points with all three miRNAs showing significant reduction in expression at the 3 day time 
point. Only miR-183 and -96 expression reduced significantly at the 24hr mark, while only 
miR-183 and -182 showed significant reduction at 7 days post LD 
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Figure 3. 4 Temporal expression of selected miRNAs  
Expression of 10 miRNAs at 24hr, 3 and 7 days post exposure. A: miRNAs showing 
progressive upregulation in the post-exposure period peaking at 7days post exposure. B&C: 
miRNAs showing highest levels of expression at 3 days post exposure. D: miRNAs showing 
downregulation at 24hr and during the post exposure period. The expression trend for all 
miRNAs was significant based on a one-way ANOVA analysis (P<0.05). 
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Table 3. 4  
List of microRNAs and the predicted gene targets 
implicated in inflammation 
miRNA ID Gene 
Symbol 
Gene Names 
mmu-miR-467d Il20rb interleukin 20 receptor beta 
mmu-miR-467c Cd14 CD14 antigen 
mmu-miR-466h Myd88 myeloid differentiation factor 88 
mmu-miR-466d-5p Rela v-rel reticuloendotheliosis viral 
oncogene homolog A 
mmu-miR-125b-3p Ccl4 chemokine (C-C motif) ligand 4 
mmu-miR-155 Chst2 carbohydrate sulfotransferase 2 
mmu-miR-207 Il1b interleukin 1, beta 
mmu-miR-351 Tnfrsf1a tumor necrosis factor receptor 
superfamily, member 1a 
mmu-miR-449a Il23r interleukin 23 receptor 
mmu-miR-494 Cxcl11 chemokine (C-X-C motif) ligand 11 
mmu-miR-509-3p Gal galanin prepropeptide 
mmu-miR-542-3p Ccl12 chemokine (C-C motif) ligand 12 
mmu-miR-685 Nfkbiz nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
inhibitor, zeta 
rno-miR-347 Ccl7 chemokine (C-C motif) ligand 7 
mmu-miR-300 Cxcl10 chemokine (C-X-C motif) ligand 10 
mmu-miR-715 Il6 interleukin 6 
mmu-miR-720 Tnf tumor necrosis factor 
mmu-miR-220 Ccl3 chemokine (C-C motif) ligand 3 
mmu-miR-582-3p Cxcl1 chemokine (C-X-C motif) ligand 1 
 Spn sialophorin 
 Hmox1 heme oxygenase (decycling) 1 
 Agt angiotensinogen 
 Jak2 Janus kinase 2 
 Sbno2 strawberry notch homolog 2 
 Clcf1 cardiotrophin-like cytokine factor 1 
 Zfp36 zinc finger protein 36 
 Cd276 CD276 antigen 
 Ier3 immediate early response 3 
 Pla2g4a phospholipase A2, group IVA 
 Alox5ap arachidonate 5-lipoxygenase 
activating protein 
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3.4 DISCUSSION 
The results of this study show that miRNAs are modulated in response to LD. Indeed, two of 
the most highly regulated gene clusters targeted by these miRNAs are ‘positive regulation of 
the transcription from RNA polymerase II promoter’ and ‘negative regulation of DNA 
dependent transcription’. This essentially reflects that light damage causes regulation of the 
retinal transcriptome. The other clusters include genes that regulate cell proliferation, cell 
adhesion, angiogenesis and our target category, the inflammatory response.  
3.4.1 FEATURES OF THE LIGHT DAMAGED RETINA 
LD-mediated retinal degeneration has been studied extensively since the landmark study of 
Noell et al in 1966 [102]. In LD, photoreceptors degenerate in the superiotemporal portion of 
the rat retina, at the area centralis, where there is a peak density of cones, and ganglion cell 
density is at its highest [268, 269]. In this respect the area centralis is homologous to the human 
macula. Furthermore, the protracted degeneration of photoreceptors and RPE cells triggered 
by LD in rat retina, and the associated breakdown of the blood retina barrier (BRB) mimic 
certain histopathological features of dry AMD [105, 109, 113]. Both oxidative damage and 
inflammation have roles in the pathophysiology of light-induced retinal degeneration.   
3.4.2 CELL PROLIFERATION AND ANGIOGENESIS IN LD 
A surprising finding of the functional clustering analysis is the high representation of target 
genes involved in cell proliferation and angiogenesis, since neither of these functions feature 
prominently in the LD model. There are two possible explanations for this. The first is that, 
because a single miRNA can regulate translation of multiple genes, the list of ‘target genes’ 
introduced into Partek for clustering is not necessarily the actual targets of the miRNAs we 
have identified. For example, miR-449a is enriched in both ‘inflammatory response’ and 
‘angiogenesis’ clusters exhibiting putative binding sites for interleukin 23 receptor mRNA, 
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involved in the immune response, and Angiopoietin-1 receptor mRNA, which facilitates blood 
vessel formation. 
A second possibility is that genes in cell proliferation pathways and/or angiogenic pathways 
may be upregulated so that the tissues are induced into a ‘pro-angiogenesis’, or ‘pro-
proliferation’ state, without activating all the genes required for angiogenesis or proliferation 
to take place. Proliferation of non-neuronal retinal cells (astrocytes, microglia and Müller cells) 
has been well documented in retinal degenerations including AMD as a response to intense 
retinal stress [69, 270, 271]. While angiogenesis has not been reported in the LD model 
previously, it is possible that leukostasis could cause local hypoxia leading to modulation of 
angiogenic factors, the effects of which might only be detected following much longer survival 
periods than explored here. 
3.4.3 CELL ADHESION AND INFLAMMATION IN LD 
Cell adhesion plays a role in a variety of different biological functions, including cell-cell 
interactions that are part of the immunological response. It is now well established that retinal 
degeneration that follows LD in this model is mediated by significant inflammatory processes, 
and the high representation of gene targets in this functional cluster might be expected on this 
basis. We have previously identified a range of inflammatory genes up-regulated following 
LD. These include several that encode proteins of the complement system (CFD, C3, C1s, C4b, 
C5r1) along with several chemokines/cytokines (CCL2, MCP-3, A21a, A6) [97, 119, 120, 272, 
273] involved in recruitment of macrophages, monocytes and other leucocytes. Some have also 
been associated with AMD, including C3, CCL2 and CX3CL1 [94, 274, 275].  
3.4.4 EXPRESSION TIMECOURSE OF MIRNAS POST LIGHT EXPOSURE 
In this study we find 8 out of 37 miRNAs that are involved in various aspects of regulation of 
the immune response. Further, our qPCR findings show that 7 out of these are modulated across 
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the 7 day timecourse of the experiment. MiR-467d showed inconsistent and/or undetectable 
fold change values across the timecourse potentially due to low target abundance. Hence, its 
significant upregulation in the miRNA Array analysis could be attributed to a false positive 
result as a result of the ‘Monte Carlo effect’ [276].    
While all 7 of the 8 selected miRNAs are upregulated post 24hr light damage, in parallel with 
the TUNEL positive cells in the ONL, only 2 (351 and 542-3p) continue to rise after 3 days 
post-exposure. Those that reach peak expression at 3d most likely have roles in the acute phase 
of retinal damage, while 351 and 542-3p are more likely to mediate changes in the retinal 
environment during the post-acute phase of degeneration in this model. While miR-351 is 
associated with neuronal and myogenic progenitor cell differentiation [277, 278], and miR-
542-3p has been reported to inhibit tumor angiogenesis [279], their roles in retinal remodeling 
after LD remain to be determined.  
The long-term effects of acute bright light exposure are well known [105, 113] and this new 
data provides insight into genes that may be key players during this phase. The targets of these 
2 miRNAs include the chemokines CXCL1 and 10, IL6, TNF, and CD276. CXCL1 and 10 are 
small molecules belonging to the CXC chemokine family and function as chemoattractants 
responsible for leukocyte trafficking. While not much is known about their role in AMD or 
light induced retinal degeneration they have been shown to facilitate the recruitment of 
lymphocytes to lesion site in atherosclerosis and other inflammatory conditions of the 
cardiovascular system [280]. Both IL6 and TNF are potent pro-inflammatory cytokines 
implicated in a wide variety of inflammation-associated disease states. Of these TNF-alpha 
(one of the most common forms of TNF) has been looked at extensively in AMD and shown 
to express readily by macrophages present in the choroidal neovascular (CNV) membranes of 
AMD patients [281]. Additionally, anti-TNF agents are currently being used as a therapeutic 
strategy for wet AMD [282].           
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Five miRNA demonstrate peak expression at 3d post-exposure. Of particular interest is the 
upregulation of miR-155 (increased 55-fold) which facilitates the inflammatory response [283] 
and targets complement factor H (CFH) [199], a major inhibitor of the alternative complement 
pathway. The Y402H SNP in the CFH gene is a major risk factor for AMD and multiple 
variants confer elevated or reduced risk of the disease [2, 3]. MiR-155 binds directly to the 3’-
UTR of CFH to facilitate activation of the complement pathway in Alzheimer’s Disease [284]. 
In vitro, miR-155 favors the pro-inflammatory (M1) polarisation of immune cells by repressing 
expression of anti-inflammatory (M2) characteristic proteins [285, 286], and miR-155 deficient 
mice have a reduced inflammatory macrophages response [267]. Peak expression of miR-155 
in this model at 3 days post light-exposure, correlates well with our previous findings showing 
peak M1 immune cell recruitment at the site of damage at 3d [98]. 
MiR-207 is upregulated in response to neurotrophins [287], that promote photoreceptor cell 
survival [288]. Peak expression of mir-207 at 3 days may reflect an attempt by the retina to 
protect its remaining photoreceptor cell population. In addition, upreguation of miR-207 might 
sustain the downregulation of one of its predicted targets Carbohydrate (N-Acetylglucosamine-
6-O) Sulfotransferase 2 (CHST2), which stimulates the formation of L-selectins on vascular 
endothelial cell surfaces, to mediate adhesion of lymphocytes around the sites of inflammation 
[289]. Less is known about MiR-125b-3p, which also had peak expression at 3 days post light 
exposure, and recently been shown to be a potential biomarker for inflammatory bowel disease 
[290]. 
Two other miRNAs reaching peak expression at 3d are miR-347 and miR-449a. Neither has 
been previously implicated in modulating the inflammatory immune response. MiR-347 
promotes neuronal apoptosis [291] and miR-449a is a known tumor suppressor that promotes 
cell death [292, 293]. Our analysis shows that all 5 miRNAs have putative binding sites in the 
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3’UTR s of chemokine, cytokine and other inflammatory effector proteins (Table 3.4), 
indicating that further characterisation of their roles in inflammation is warranted.  
It is evident from the above expression profiles that majority of the inflammation related 
miRNAs show a rapid and sustained increase in expression due to bright light exposure, 
implying a stricter translational control of their respective targets. However, we know from our 
previous studies that many cytokines and chemokines (including the ones identified as targets 
in this study) exhibit increased expression due to bright light exposure [96, 98]. This 
discrepancy in the expression levels of miRNAs and their target genes could be a facet of the 
complex regulatory networks, compensatory or otherwise, that are at play inside cells/tissues 
during ageing, disease and/or damage. Furthermore, there is a growing body of evidence 
supporting the hypothesis that expression levels of some miRNAs may be directly proportional 
to the amount of target sites available. A phenomenon known as ‘Target Mediated miRNA 
Protection’ (TMMP) [294].      
We also analysed the expression pattern of miRNAs of the miR183/96/182 cluster (Figure 4D) 
which have been shown to occur selectively in the photoreceptor layer. Previous studies have 
implied the role of this cluster in normal photoreceptor morphogenesis and functioning, 
maintaining the retinal circadian cycle and playing a protective role in bright light induced 
retinal degeneration [295, 296]. Unlike Zhu and colleagues who showed an upregulation of 
these miRNAs due to environmental light conditions (30minute exposure to 10,000 lux light), 
our model shows a downward expression trend under a more sustained (24hr) exposure of 
bright (1000 lux) light. This discrepancy could be due to the more chronic degenerative state 
of the retina in our experimental paradigm inherent in retinal degenerations. Or simply a 
consequence of the timing differences between the two studies when the miRNA expression 
was analysed.    
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While this study gives us a good indication of the different miRNAs that are potentially 
responsible for modulating retinal inflammation. It is does not give us an exhaustive list of 
miRNAs being modulated by high intensity light, since the global miRNA screening was 
conducted only at the 24hr mark. Additionally, since RNA from the whole retina was used for 
this study, it was not possible to account for the inherent variations between the inferior and 
superior retina. Which may have contributed to the large variability seen in the 24hr LD data 
in figure 3.2.  
3.4.5 CONCLUSION  
In this study we identify 37 miRNA regulated by 24hr LD, including 7 that regulated the 
inflammatory response, which is a key mediator of retinal degeneration in this model and in 
AMD. MiRNA are endogenously-occurring molecules that can be safely introduced in-vivo 
without triggering a non-specific immune response. Because these miRNAs regulate multiple 
genes and pathways simultaneously they provide new potential therapeutic targets with far-
reaching biological outcomes suitable for management of complex retinal disorders, like AMD.  
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CHAPTER 4: MICRORNA-124-3P 
REGULATION OF A POTENT PRO-
INFLAMMATORY CHEMOKINE IN 
RETINAL DEGENERATIONS  
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4.1 INTRODUCTION 
Recently microRNAs have been shown to be involved in the pathogenesis of AMD [297]. 
MicroRNAs are a class of small, endogenous, non-coding RNA molecules that are potent 
negative regulators of gene expression which act by binding to complementary sequences in 
the 3’UTRs of their messenger RNA (mRNA) targets [131, 132, 135]. Since their discovery 
just over a decade ago, microRNAs have emerged as critical regulators of gene expression 
affecting multiple biological processes including development and differentiation, apoptosis 
and cell proliferation [298]. It has been estimated that miRNAs have the potential to regulate 
over 60% of protein coding genes in mammals [299]. They have also been identified to have 
critical roles in a myriad of diseases including various cancers [300], obesity, diabetes, 
neurological disorders and inflammation [301]. Their therapeutic potential as drug targets is 
well recognized, with a miRNA-based therapy already in Phase 2 clinical trial (for Hepatitis 
C) [302].   
Activation of the innate immune system and recruitment of inflammatory cells to the retina is 
a significant factor in progression of AMD [21]. Although the precise mechanisms underlying 
this targeted recruitment is unclear, a family of chemotactic molecules (chemokines) have been 
implicated. Recent gene expression studies of AMD donor eyes have shown CCL2 (among 
other chemokines) to be up-regulated in both the neovascular and atrophic forms of the disease 
[93]. A light damage model of retinal degeneration, that mimics the inflammatory aspects of 
‘dry’ AMD progression, identified up-regulation of CCL2 [96] by microarray analyses and 
have shown that silencing CCL2 mRNA using a Ccl2-siRNA attenuates recruitment of 
inflammatory cells to the site of damage, resulting in reduction of both photoreceptor cell death 
and RPE atrophy [97]. We reason that because targeted reduction of CCL2 in retinal cells in 
this model is protective against the progression of retinal degeneration, it may have a similar 
effect in AMD.     
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Abundant in the central nervous system, miR-124a was initially believed only to drive neuronal 
cell differentiation [8]. Recent studies, however, have shown that miR-124 also plays an 
important role in modulating a number of CNS disorders (reviewed in [303]) including an 
important role as a driver of the inflammatory immune response in certain cell types [304], 
including modulation of CCL2 expression [305]. 
In this study, we demonstrate the modulation of miR-124-3p expression in both light-damaged 
rat retina (in vivo) and immortalized retinal cell lines. Using in situ hybridization we have 
localized miR-124-3p expression in rat and human retinae to Müller cells, and confirmed in 
vitro, that miR-124-3p directly targets Chemokine (C-C motif) ligand 2 (CCL2) using an 
immortalized Müller cell line.  
 
4.2 METHODS 
4.2.1 ANIMAL HANDLING AND LIGHT DAMAGE 
Animals were handled and treated in accordance with the ARVO, ethical use of animal in vision 
research statement. Sprague Dawley (SD) rats were born and reared in dim cyclic light 
conditions of approximately 5 lux. The animals were exposed to bright continuous light 
between post-natal days 100-150 at an intensity of 1000lux for 24hrs starting at 9am. The light 
source used was white fluorescent light (COLDF2 2 3 36W IHF; Thorn Lighting, Brisbane, 
Australia) placed overhead with each animal in its own transparent perspex cage to ensure 
uniform illumination. Rodent food pellets were provided next to the bedding to minimize 
interference with light exposure and water was provided ad-libitum. After the 24hr light 
exposure some animals were immediately euthanized by intraperitoneal injection of barbiturate 
overdose or returned to dim light conditions (5lux). These animals were euthanized 3 or 7 days 
post return to dim reared conditions. We used age matched dim reared animals as controls. 
 84 
4.2.2 TISSUE COLLECTION AND PROCESSING  
The animals were euthanized by administering an intraperitoneal injection of barbiturate 
overdose (60mg/kg). The retinas from the right eye of the animals was excises via a corneal 
incision and stored in cold Trizol solution on ice before proceeding with the RNA extraction. 
Total RNA, including miRNAs, was extracted using the mirVana miRNA isolation kit 
(Ambion, Applied Biosystems) and concentration determined with the ND-1000 
spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). The left eye of the 
animals was enucleated, superior region marked and processed for sectioning. Eyes for 
cryosectioning were immersed in 4% paraformaldehyde for 3 hours, anterior chamber 
(including lens) removed and replaced in 4% paraformaldehyde for 24hrs. The eyes were then 
processed for paraffin coating and embedding before sectioning at 4-6um on the microtome, 
across the superior-inferior axis. Adult human eyes were obtained through the Lions Sydney 
Eye Bank. Tissue was processed in accordance with a previously established protocol as 
described in [44]. Age matched normal and AMD affected human retinal tissue was 
cryosectioned at 10 µm.      
4.2.3 ANALYSIS OF CELL DEATH 
TdT-mediated dUTP nick end labelling (TUNEL) labelling technique was used to quantify 
photoreceptor cell death over the light damage time course, in retinal cryosections using a 
previously published protocol [96]. TUNEL+ cells were counted in the ONL along the full 
length of the retinal sections cut the superioinferior plane, including the optic disc, at 1mm 
intervals across the retinal sections. The final counts for each experimental group is the average 
of five animals counted at comparable locations. Prism (GraphPad Software V5) was used for 
statistical analyses by one-way ANOVA and Student’s t-test.       
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4.2.4 MICRORNA QUANTITATIVE REAL-TIME PCR 
cDNA was synthesized using TaqMan MicroRNA RT kit (Applied Biosystems) as described 
previously (Saxena et al 2015). Expression of miR-124-3p was quantified using miRNA 
specific commercially available TaqMan hydrolysis probes (Applied Biosystems), enlisted in 
Table 4.1. Fold Change was determined using the ΔΔCt method and expression normalized to 
endogenous small nuclear U6 RNA. Amplification specificity was assessed using gel 
electrophoresis and statistical analysis was performed using 1-way ANOVA and Student’s t-
test. 
4.2.5 IN SITU HYBRIDISATION AND IMMUNOHISTOCHEMISTRY 
In situ hybridization was performed to localize miRNA expression in the retina using 
commercially available double DIG labelled miR-124-3p miRCURY LNA probe (Exiqon) and 
miRCURY LNA™ microRNA FFPE ISH detection kit 4, according to manufacturer’s 
protocol; Paraffin was stripped off the rat retinal sections using xylene washes and rehydrated 
by washing in a decreasing concentration of ethanol. All retinal sections (Human and Rat) were 
treated with proteinase K (20µg/ml) for 10 minutes. MiR-124-3p probe was hybridized for 1.5 
hours at 53°C and then washed in saline sodium citrate at 58°C. Bound probe was visualized 
with HNPP/Fast-Red (Roche, Basel, Switzerland), which was followed by counter-staining 
using immunohistochemistry.  
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Table 4. 1 
TaqMan® probes used 
Gene Symbol Name Accession # Catalog # 
Ccl2 Chemokine (C-C motif) ligand 2 NM_031530.1 Rn01456716_g1 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
NM_017008.3 Rn99999916_s1 
miR-124-3p mmu-miR-124a MIMAT0000422 001182 
U6 snRNA U6 small nuclear RNA NR_004394 001973 
 
 87 
In situ stained sections were incubated with primary antibody overnight at 4°C, raised against 
Vimentin (1:200; Sigma-Aldrich, St. Louis, MO, USA). Sections were then incubated with 
secondary antibody, conjugated to Alexa488, raised against mouse IgG’s (1:200; Life 
Technologies, Carlsbad, CA, USA) for 2-4 hrs at room temperature. Slides were then cover 
slipped with Aqua Poly/Mount (Polysciences, Warrington, PA, USA). Immunoflourescence 
was viewed using a Zeiss laser scanning microscope, while PASCAL software was used for 
acquisition.  
4.2.6 QUANTITATIVE REAL-TIME PCR 
Quantitative PCR was used to measure the expression of CCL2. First-strand cDNA systhesis 
was performed using Tetro cDNA Synthesis Kit (Bioline, London, UK) according to 
manufacturer’s instruction. A 20-µl reaction mixture, including 500 ng to 1 µg RNA, 200 U 
Tetro Reverse Transcriptase, 4 µl 5x RT buffer, 500 ng oligo (dT)18 primer mix and 10 U 
RNase Inhibitor. Gene amplification was measured using commercially available TaqMan 
hydrolysis probes (Table 4.1), in accordance with a previously established qPCR protocol 
[306]. Fold change was determined using ΔΔCt method where CCL2 expression was 
normalized to that of reference gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Statistical analysis were performed using 1-way ANOVA and Student’s t-test.      
4.2.7 CELL CULTURE 
Cell culture experiments were performed using HeLa cells and low passage (<10) immortalized 
human Müller cell line (MIO-M1). We also used a low passage 661W photoreceptor cell line, 
generously provided by Dr. Muayyad Al-Ubaidi (University of Oklahoma), and an 
immortalized RPE cell line (ARPE19) for this study. Cells were used within 10 passages of 
authentication and validation from Cell Bank Australia and were further validated using RT-
PCR for expression of cell specific markers (SW opsin, M opsin pigments, SV40 for 661W 
cells; RPE65, RLBP1 for ARPE19 cells; GFAP, Vimentin for MIO-M1 cells). Cells were 
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cultured in Dulbeco’s Modified Eagle’s Medium (DMEM; Invitrogen) containing 10% fetal 
bovine serum, L-glutamine (3 mM), sodium pyruvate (1 mM) and glucose (25 mM) and stored 
in an incubator at 37°C, 5% CO2. Human IL-1β protein (Cat#, PHC0811, ThermoFisher) 
(10ng/ml) was used as a pro-inflammatory stimulus for MIO-M1 and ARPE19 cell lines. 
While, 661W photoreceptor cells were stimulated by bright light induced damage. The cell 
culture plate, containing 80-90% confluent cells, was placed under 15,000 lux light for 5 hours 
while inside an incubator maintained at 37°C and 5% CO2 to ensure even distribution across 
the plate. The temperature of the setup was monitored vigilantly using a thermometer placed 
next to the culture plate.    
4.2.8 LUCIFERASE REPORTER ASSAY 
Luciferase assay was performed on both HeLa and MIO-M1 cells using a commercially 
available vector containing the luciferase gene fused to the human CCL2 3’UTR (CCL2 
LightSwitch 3’UTR Reporter GoClone; Switchgear Genomics, CA, USA) and pLightSwitch-
3’UTR Luciferase assay system (Switchgear Genomics, CA, USA), following the 
manufacturer’s protocol (refer Figure 4.1). HeLa cells were seeded in a 96 well plate (5000 
cells per well) and cultured for 24hrs. At ~90% confluence, the cells were transfected with the 
vector only, co-transfected with the vector plus miR-124-3p mimic (Ambion) or co-transfected 
with the vector plus negative control miRNA mimic (Ambion) using Viafect (Promega) and/or 
Lipofectamine RNAiMAX (Invitrogen) for 48hrs. pLightSwitch Luciferase assay system was 
performed according to manufacturer’s protocol and luciferase activity measured by Infinite® 
200 plate reader (TECAN, Austria). MIO-M1 cells were seeded in a 96 well plate (3000 cells 
per well), cultured for 24hrs and transfected with the vector only using viafect (Promega) 
transfection agent. After 36hrs cells were treated with 10ng/ml IL1ß protein for a duration of 
12hrs, following which the luciferase assay was performed and luciferase activity measured. 
Statistics were performed using Student’s t-test.  
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Figure 4. 1 LightSwitch 3’UTR reporter assay   
Schematic diagram showing the luciferase assay performed on HeLa and MIO-M1 cells to 
confirm miR-124-3p and Ccl-3’UTR interaction. A 3’UTR, of a gene of interest, cloned into a 
LightSwitch 3’UTR reporter vector is co-transfected with miRNA mimics. The relative amount 
of light (bioluminescence) produced in wells containing candidate miRNA vs control miRNA 
are used to measure the effect of miRNA-3’UTR interaction on translation of the hybrid 
RenSP-3’UTR mRNA transcript.      
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4.2.9 TRANSFECTION OF MIR-124-3P MIMIC AND INHIBITOR INTO MÜLLER CELLS  
MIO-M1 cells were seeded in clear plastic 6-well tissue culture plates at a density of 80,000 
cells per well and the medium was replaced with low serum (1%) DMEM after sufficient 
adhering time. Cells were incubated at 37°C in 5% CO2 for 12h and transfected with 10nM 
miR-124-3p mimic, miR-124-3p inhibitor or negative control miRNA mimic (Ambion), using 
Lipofectamine RNAiMAX (Invitrogen). After 24hrs cells were exposed to 10ng/ml IL-1b 
protein for a duration of 12hrs. The cells were then harvested using TRIzol (Invitrogen) reagent 
and RNA extracted using the RNAqueous-Micro RNA Isolation Kit (Ambion, Applied 
Biosystems). cDNA was synthesized and qPCR performed using TaqMan hydrolysis probes 
for CCL2 as described previously. CCL2 expression for the different experimental groups was 
compared back to that of the non-transfected/treated MIO-M1 cells. Transfection efficiencies 
in each experimental setup were assessed by co-transfecting a fluorescently tagged negative 
control oligonucleotide (BLOCK-iT™, Invitrogen) at 10nM concentration.   
4.2.10 TRANSFECTION OF MIR-124-3P MIMIC IN VIVO  
Both miR-124-3p and negative control miRNA mimic (Ambion) were used for in vivo 
transfections. Before administration, miRNAs were encapsulated in a cationic lipid based 
transfection agent (Invivofectamine 2.0, Invitrogen) according to the manufacturer’s protocol. 
Each encapsulated miRNA was formulated to a final concentration of 0.33 µg/µl in 1x PBS 
solution.  
Animals were anaesthetized with an intraperitoneal injection of 30mg ketamine (Troy 
Laboratories) and 3mg xylazil (Parnell) to perform intravitreal injections. A drop of 1% 
atropine (Chauvin Pharmaceuticals) was applied to the corneal surface to produce mydriasis, 
and the injection site (0.5mm posterior to the temporal limbus) was swabbed with 5% povidone 
iodine (Betadine, Faulding Pharmaceuticals). Intravitreal injections were then performed as 
described previous by Gao and colleagues [307]. 3µl of either miR-124-3p or negative miRNA 
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mimic complex was injected into both eyes of each animal, corresponding to 1ug miRNA 
mimic per eye. As an additional control, 3µl of transfection agent only (processed through the 
same steps as the miRNA mimic complexes) was injected into both eyes of some animals. 
Finally, in order to prevent infection at the injection site, 5mg/g neomycin ointment (Amacin, 
Jurox) was applied after injection. Post injections, all animals were returned to dim (5lux) light 
conditions for 24hrs prior to initiation of light damage. Transfection efficiencies were assessed 
by co-transfecting a fluorescently tagged negative control oligonucleotide (BLOCK-iT™, 
Invitrogen) at 10nM concentration (according to manufacturer’s recommendations).  
The biological effect of the in vivo transfections was assessed by analysing IBA 1 
immunoreactivity of the different retinal sections, following immunohistochemistry protocol 
mentioned in section 4.2.5. IBA 1 or ionizing calcium binding adaptor molecule 1 is a novel 
protein specifically expressed in microglia and macrophages and is used extensively as a 
marker for these cells in various tissue types including the retina. Hence immunoreactivity for 
IBA 1 can identify microglia or macrophages in both their resting and activated forms.        
 
4.3 RESULTS 
4.3.1 TIME COURSE OF PHOTORECEPTOR CELL DEATH AND MIR-124-3P 
EXPRESSION IN VIVO 
Following light damage, TUNEL+ nuclei were identified in the ONL/photoreceptor layer, and 
were more numerous in the superior retina. The average number of TUNEL+ photoreceptor 
cells reached a peak at 24 hours of bright light exposure (P < 0.001, student’s t-test) consistent 
with our previous reports. During the post-exposure period, the number of TUNEL+ nuclei 
was reduced to ~40% of peak levels at 3 days and to ~33% after 7 days (P < 0.01, student’s t-
test).   
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We assessed the modulation of miR-124-3p expression across this timecourse, using qPCR 
(Figure 4.2). Exposure to damaging light led to significant reduction of miR-124-3p expression 
in the retina, relative to levels of expression in dim-reared animals (P<0.05; one-way ANOVA; 
Figure 4.2). At 24 hours exposure we detected a 287% decrease (P<0.01) in miR-124-3p 
expression compared to the dim-reared animals. This downregulation of expression did not 
change appreciably at 3 and 7 days post exposure (Figure 4.1B). 
4.3.2 LOCALISATION OF MIR-124-3P EXPRESSION IN THE RAT RETINA 
Localisation of miR-124-3p in the retina was analysed by in situ hybridisation in retinas from 
dim-reared and light damaged animals (Figure 4.3). In dim-reared retinas mature mir-124-3p 
was observed in a dense band at the outer extremity of the ONL, suggestive of the External 
Limiting Membrane (ELM) (Figure 4.3A; arrowheads). In light damaged retinas we detected 
increased expression of miR-124-3p expression in the INL, with staining visible in cells and 
radial processes (Figure 4.3B; Arrow heads). Fluorescent markers showed that mature miR-
124-3p co-localized with vimentin-immunoreactive Müller cell end feet and processes (Figure 
4.3C-D; Arrows) in dim-reared and in light damaged retinas, suggesting that miR-124-3p is 
expressed by Müller cells. 
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Figure 4. 2 Photoreceptor cell death vs miR-124-3p expression  
Quantification of apoptotic photoreceptors and miR-124-3p expression across LD timecourse. 
Photoreceptor cell death reached a peak of 470 by 24hrs of exposure (P<0.001), followed by 
significant decrease during the post exposure period (P<0.01). MiR-124-3p expression showed 
a significant dowregulation due to light damage (-287%; P<0.01). This decrease in expression 
was sustained up to 7 days post exposure (-277%; P<0.0001). TUNEL n=5; miR-124-3p 
expression n=11; error bars represent SEM. ‘*’ denotes significance based on Student’s t-test 
with P<0.05, ‘**’ P<0.01, ‘***’ P<0.001 and ‘****’ P<0.0001. 
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In situ hybridisation for miR-124-3p 
expression in the light damaged rat 
retina. A-D: Representative images 
show In situ hybridisation for miR-124-
3p (Red) and Müller cells (Vimentin, 
Green). In dim-reared retinas, 
expression of miR-124-3p was observed 
as a strong band at the junction of ONL 
and photoreceptor inner/outer segments 
(A and C; Arrowheads/Arrows). After 
LD the expression was observed more 
inwards in radial processes present in 
the INL (B andD; Arrowheads/Arrows). 
The expression in both dim-reared and 
LD retinas was closely associated with 
Müller glia labelled with Vimentin (C 
and D). INL, inner nuclear layer; ONL, 
outer nuclear layer; Scale bar (A-D) 
represents 25µm. 
 
       
 
 
 
 
 
 
 
Figure 4. 3 MiR-124-3p in situ 
hybridisation in rat retina 
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4.3.3 EFFECT OF IL1ß ON MIR-124-3P AND CCL2 EXPRESSION IN-VITRO 
Using qPCR, we tested three cell lines (MIO-M1, ARPE19 and 661W) for expression of miR-
124-3p. Only MIO-M1 cells (Müller cell line) showed significant modulation (P<0.05) of miR-
124-3p after stimulation with pro-inflammatory IL1β (Figure 4.4A). The effect of prolonged 
pro-inflammatory stimulation on both miR-124-3p and CCL2 expression indicates that IL1β 
results a significant downregulation of miR-124-3p (P<0.05) expression, and simultaneous 
upregulation of CCL2 (P<0.05) across the exposure timecourse (Figure 4.4B). For the sake of 
consistency all further experiments utilised 12hours exposure duration. 
4.3.4 MIR-124-3P INHIBITS CCL2 THROUGH DIRECT 3’UTR BINDING 
To validate a functional interaction between miR-124-3p and CCL2 mRNA in our system, we 
used a vector containing luciferase gene fused to the human CCL2 3’UTR sequence. When 
HeLa cells were co-transfected with miR-124-3p mimic the luciferase reporter signal was 
significantly reduced (by ~50%, P<0.001) of levels obtained by co-transfection with scrambled 
miR (negative control), indicating binding of the miRNA mimic to the vector (Figure 4.5A).  
Transfection of the luciferase-CCL2 3’UTR vector into MIO-M1 cells established baseline 
reporter signal levels (untreated, Figure 4.5B). After challenge with 10ng/ml IL1β protein the 
luciferase reporter signal in MIO-M1 cells increased by 50-60% above baseline (Figure 4.5B, 
P<0.01) indicating decreased binding of the mimic to the target sequence.   
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Figure 4. 4 MiR-124-3p and CCL2 expression in retinal cell lines 
Expression of miR-124-3p and CCL2 by different retinal cell types under inflammatory or 
damaging stress in vitro. A: MiR-124-3p expression did not change appreciably in ARPE19 
cells stimulated with IL1β nor 661W cells damaged by high intensity light, while a significant 
downregulation was observed in MIO-M1 cells stimulated with IL1β (one-way ANOVA; 
P<0.05). B: The expression of CCL2 elevates significantly in MIO-M1 cells stimulated with 
IL1β across the exposure duration, while miR-124-3p shows significant downregulation 
simultaneously (one-way ANOVA; P<0.05). MIO-M1, 661W, ARPE19 cells n=9 (A); MIO-
M1 cells (B) n=8; error bars represent SEM. ‘*’ denotes significance based on Student’s t-test 
with P<0.05. 
 
 97 
 
Figure 4. 5 Luciferase assay to confirm miR-124-3p/CCL2 interaction 
Luciferase assay to validate miR-124-3p and CCL2 interaction in HeLa cells (A) and MIO-M1 
cells (B). A: Co-transfection of HeLa cells using a vector containing the human CCL2-3’UTR, 
fused to luciferase gene, with a miR-124-3p mimic induced a significant reduction in luciferase 
activity compared to cell co-transfected using the vector with negative control miRNA mimic 
(P<0.001; n=8). B: MIO-M1 cells transfected with the CCL2-3’UTR-Luciferase vector show 
a significant increase in luciferase activity after IL1β protein challenge (P<0.01; n=9). Error 
bars indicate SEM. Significance based on student’s t-test. 
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4.3.5 OVEREXPRESSION OF MIR-124-3P IN MIO-M1 CELLS DOWN-REGULATES 
INFLAMMATORY CHEMOKINE (CCL2) IN VITRO 
To assess the efficiency, specificity and biological impact of the miR-124-3p mimic, we 
transfected MIO-M1 cells in vitro with biomimetic miR-124-3p, a specific inhibitor, or 
negative control miRNA, then challenged cells with IL1β. Figure 4.6 shows that non-
transfected MIO-M1 cells showed an increase in CCL2 expression of ~390% (P<0.01) after 
challenge with IL1β. However, MIO-M1 cells transfected with miR-124-3p mimic showed 
virtually no change in CCL2 expression, compared to controls. MIO-M1 cells challenged with 
IL1β, but transfected with miR-124-3p inhibitor or negative control miRNA, showed no 
significant change in CCL2 expression compared to non-transfected controls. 
4.3.6 IN SITU LOCALISATION OF MIR-124-3P 
To test the relevance of these experiments to potential modulation of CCL2 expression in the 
human retina we used in situ hybridization for miR-124-3p in human retinal sections from a 
normal post mortem donor, and one with AMD. We detected expression of miR-124-3p in the 
normal retina in cells in the INL, in radial processes, and at the junction of the ONL and 
photoreceptor inner segments (Figure 4.7A, arrowheads). This expression pattern is very 
similar to that seen in the rat retina (Figure 4.3) and is suggestive of miR-124-3p expression in 
Müller cells. We detected little to no miR-124-3p expression in the foveal region of the AMD 
affected tissue (Figure 4.6B), consistent with the qPCR data shown in Figure 4.2.  
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Effect of miR-124-3p mimic and inhibitor on CCL2 expression in MIO-M1 cells in vitro. The 
upregulation of CCL2 expression in IL1β stimulated MIO-M1 cells was significantly reduced 
down to basal expression level by miR-124-3p mimic transfection (P<0.01). While, negative 
control miRNA mimic and miR-124-3p inhibitor transfection had no appreciable effect on the 
CCL2 upregulation. n=9; error bars represent SEM. ‘Untreated’ refers to MIO-M1 cells 
without any transfections or IL1β exposure. Significance based on Student’s t-test. 
     
 
 
 
 
Figure 4. 6 Effect of miR-124-3p knockin on CCL2 expression in vitro  
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Figure 4. 7 MiR-124-3p in situ hybridisation in human retina 
In situ hybridisation for miR-124-3p expression in normal and AMD affected human retina. 
Representative images demonstrate in situ hybridisation for miR-124-3p at the parafoveal 
region of normal (A) and AMD affected (B) human retinas. A: An abundance of miR-124-3p 
expression is evident in the normal retinal tissue at the outer edge of the ONL as well as in 
radial processes distributed across the INL (Arrowheads). B: In contrast, much less staining 
for miR-124-3p expression (Red) was observed in the AMD affected retina. C: The negative 
control miRNA In situ probe (Scrambled) was not detectable in the retinal tissue sections. (n=3)  
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4.3.7 FUNCTIONAL ANALYSIS OF MIR-124-3P OVEREXPRESSION IN VIVO 
To investigate the biological impact of miR-124-3p in modulating retinal inflammation in the 
rat retina, we attempted its overexpression by in vivo transfection of synthetic miR-124-3p 
mimics using intravitreal injections (Figure 4.8). Followed by assessment of IBA1 reactivity 
in the different experimental rat retinas. We saw a significant difference in the distribution of 
IBA1 positive cells in the retina between miRNA + Invivofectamine 2.0 or Invivofectamine 
2.0 only injected and dim-reared or light damaged only groups. While dim-reared retinas show 
a uniform distribution of ramified (resting) cells and light damaged retinas show preferential 
localization in the ONL and OPL layers at the superior region. Light damaged retinas from 
animals injected with either Invivofectamine 2.0 only or Negative control miRNA mimic or 
miR-124-3p mimic showed specific localisation of amoeboid (activated) cells at the inner edge 
throughout the retina. 
  
4.4 DISCUSSION 
This study demonstrates a role of miR-124-3p in modulating CCL2 expression in the retina, 
including its role in the inflammatory response in retinal degeneration. The findings show that 
miR-124-3p expression is inversely correlated to photoreceptor cell death in the degenerating 
rat retina, that its expression is predominantly localized to the Müller glia, and that it has a 
specific function in modulating expression of the chemokine CCL2. We have confirmed the 
interaction of miR-124-3p and CCL2 mRNA using luciferase reporter assays and used in vitro 
approaches to demonstrate specific suppression of pro-inflammatory CCL2 by miR-124-3p. 
We also show using in situ hybridization that miR-124-3p has a similar expression profile in 
both human and rat retinas in a pattern that is consistent with Müller cell distribution, and that 
in the rat retina miR-124-3p undergoes a redistribution from labelling predominantly in the 
external limiting membrane to the INL.  
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Figure 4. 8 Effect of in vivo transfection of miR-124-3p mimic in rat retina 
Immunoreactivity for IBA1 (red) in the retina following in vivo transfections using 
Invivofectamine 2.0. Representative images of the superior mid-periphery demonstrate IBA1 
positive cell distribution. A: Normal distribution of IBA1+ cells localised in the inner retina. 
B: IBA1+ cells are present in the ONL and OS regions after light induced damage. C-E: 
Retinas injected with Invivofectamine2.0® (with or without miR-Negative mimic/miR-124-3p 
mimic) prior to light damage show a presence of activated IBA1+ cells at the inner edge of the 
retina (Arrowheads). 
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MicroRNAs are universal regulators of protein expression that have multiple targets and are 
expressed in a tissue/cell specific manner at different stages of development and disease [164, 
308, 309]. Hence modulation in expression of a single miRNA can contribute significantly to 
pathology. The miRNA of interest in this study, miR-124-3p, is highly expressed in the CNS 
and is recognized as a critical regulator of neuronal development and differentiation [310, 311], 
but is also known to be downregulated in a range of CNS disorders (reviewed in [303]). In an 
animal model of multiple sclerosis, miR-124-3p is highly expressed in quiescent resident 
microglia  but is reduced in activated cells with the M1/pro-inflammatory phenotype during 
inflammation [312]. The authors also report that increased miR-124-3p promotes and maintains 
the M2/anti-inflammatory state of microglia and macrophages by regulating the CEBPα/PU.1 
pathway. 
Expression of miR-124-3p in the retina has been documented previously using RT-PCR in 
rodent and human retinas [310, 313-315]. However, no previous studies have looked at changes 
in miR-124 expression levels during retinal inflammation and degeneration. Here, we 
demonstrate that this decrease in miR-124 expression due to LD coincides with a dramatic 
increase in photoreceptor cell death. Previously we have shown that light-induced retinal 
damage is associated with an increase in CCL2 expression in Müller glial cells [98], and that 
CCL2 expression is associated with recruitment of complement-bearing macrophages into the 
retina, and with photoreceptor death. In this study our gene expression analysis shows that 
miR-124 expression decreases as a result of light-induced retinal degeneration consistent with 
the role of miR-124 reported in other neurodegenerative disorders (reviewed in [303]). 
Significantly, we also demonstrate that miR-124-3p modulates retinal inflammation 
specifically by targeting CCL2, which is responsible for recruitment of inflammatory immune 
cells to the site of photoreceptor degeneration. The inverse relationship between miR-124 
expression and CCL2 is consistent with previous findings in rheumatoid arthritis [305, 316].  
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Our findings also suggest that miR-124-3p may have a number of other targets in the inflamed 
and degenerating retina, since we find decreased expression as late as 7d post exposure, when 
CCL2 levels are significantly reduced, and levels of photoreceptor death have dropped 
significantly [98, 105]. Other targets for miR-124-3p mediated regulation in retinal 
degeneration therefore, remain to be identified.                 
4.4.1 MIR-124-3P LOCALIZATION TO RETINAL MÜLLER CELLS 
Previous work by Deo, Karali and colleagues [310, 314] showed that miR-124 is expressed 
throughout adult mouse retina with strong staining observed in the INL, but were unable to 
identify the specific cell type responsible for its expression. We used immunolabeling 
combined with in situ hybridization to show preferential distribution of mature miR-124-3p in 
vimentin-positive Müller glial cells. We find that in normal (unstressed) retina, mature miR-
124-3p is highly expressed in the outer end-feet of Muller cells, in the region of the ELM where 
the Müller cell end feet are found, and at lower levels in the Müller cell bodies in the INL and 
in their radial processes. After light exposure miR-124-3p is redistributed so that higher levels 
of expression are present in the Müller cell bodies in the INL, but lower levels are present in 
the outer retina. This post-exposure localization of miR-124-3p in the Müller cell somata is 
consistent with the localization of the target CCL2 mRNA. We find a similar pattern of 
expression of miR-124-3p in normal human retinal sections with reduced expression in the 
degenerated regions of the retina, consistent with a recent gene expression study reporting 
upregulation of CCL2 in both wet and dry forms of AMD [93].      
Our in vitro experiments confirm the significance of Müller cells in expression of miR-124-3p. 
We find in cell lines that MIO-M1 (Müller cells) show significant downregulation of miR-124-
3p after IL1β challenge, while there was no change in expression detected in either ARPE19 
cells or the 661W photoreceptor cell lines following an appropriate challenge (IL1β and light 
damage, respectively). IL1β is a potent pro-inflammatory cytokine that induces expression of 
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both α and β chemokines in vitro [317], in arthritis [318] and LPS-induced endotoxemia [319] 
and is significantly upregulated in our light induced model of retinal degeneration, where it 
plays broad modulatory roles in chemokine secretion [320]. Photoreceptors, including 
immortalized 661W cells, do not respond to IL1β but are induced into apoptosis following 
exposure to bright light; for this reason we chose this as the challenging stimulus in these 
experiments. As well as showing a significant down-regulation of miR-124-3p after IL1β 
challenge, we found a concomitant upregulation of CCL2 expression in the MIO-M1 cell line, 
consistent with our findings in vivo [97, 98]. 
4.4.2 FUNCTIONAL ANALYSES OF MIR-124-3P IN VITRO 
Luciferase assays using MIO-M1 and HeLa cells demonstrate a functional relationship between 
downregulation of miR-124-3p expression and upregulation of CCL2 expression, first by 
showing  a reduction in the luciferase signal in HeLa cells due to co-transfection of the CCL2-
3’UTR fused vector along with synthetic miR-124-3p compared with a scrambled miRNA 
mimic, consistent with a previous report of binding between miR-124 and CCL2 mRNA in 
E11 cell line [316].  
And secondly, by showing an increase in luciferase activity in IL1β stimulated MIO-M1 cells 
pre-transfected with the CCL2-3’UTR fused vector. As MIO-M1 cells express miR-124-3p 
endogenously, its downregulation in the presence of IL1β stimulation (as shown in figure 4.3A) 
would result in reduced translational repression of its target 3’UTR containing mRNAs. 
Thereby leading to increased translation of the vector derived luciferase gene and hence greater 
bioluminescent signal.    
Third and most importantly, our experiments show that transfection of cells with miR-124-3p 
mimics prior to IL1β challenge effectively inhibits a subsequent significant increase in CCL2 
expression in vitro (Figure 4.6).  
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Our previous work in vivo indicates that CCL2 is not expressed in the retina under normal 
conditions. It is only after photoreceptor cell death that CCL2 expression is upregulated in 
Müller cells [98] leading to localized recruitment of microglia/monocytes [70, 84, 86]. Because 
these recruited cells are complement-bearing and also express chemokines (including CCL2), 
they are part of a process that upregulates the inflammatory cascade. Targeted knockdown of 
CCL2 with siRNA reduces recruitment and photoreceptor death [97]. In these experiments we 
attempted to regulate CCL2 expression using a miRNA mimic, but without success due to 
issues of the transfection agent, which alone promoted an inflammatory response in the retina. 
Further in vivo studies are in progress using a new transfection agent provided by the 
manufacturer, but which could not be completed within the period of candidature.  
Collectively, these experiments indicate that modulation of miR-124-3p has the capacity to 
control the inflammatory environment of the retina, by modulating expression of CCL2. While 
CCL2 is not the only chemokine expressed in the degenerating retina [320], our data indicates 
that CCL2 is a non-redundant factor in retinal inflammation. These findings suggest that miR-
124-3p will prove to be a novel therapeutic target in inflammatory disorders of the retina 
including AMD [78], diabetic retinopathy [79, 80] and glaucoma [81, 82].  
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CHAPTER 5: EFFECT OF 670NM 
LIGHT TREATMENT ON 
EXPRESSION OF INFLAMMATORY 
REGULATORS AND MIRNA IN THE 
LIGHT DAMAGED RAT RETINA 
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5.1 INTRODUCTION 
The beneficial effects of light exposure in the red to near infrared (NIR) spectrum have been 
documented in a number of diseases/maladies over the past few decades [227, 321-325]. 
Recently, NIR therapies have been useful in treating a number of cardiovascular [326], 
musculoskeletal [218, 219] and central nervous system (CNS) conditions [220, 221], with 
studies in animal models showing positive effects in inflammation, neurodegeneration and soft 
tissue damage [225, 229, 237, 239, 327, 328]. It has been reported that red to NIR light is 
protective in retinal pathologies with several studies using animal models showing its ability 
to attenuate light induced retinal degeneration [96, 118, 234, 235], retinal lesion development 
in diabetic retinopathy [232], methanol toxicity [231] and degeneration during ageing [239].    
Investigations using the light induced model of retinal degeneration have shown that 670nm 
light treatment significantly reduces photoreceptor damage, preserves retinal function, 
suppresses expression of inflammatory markers and ameliorates oxidative stress in light 
damaged retinas [118, 233, 234, 236]. However, none of these have looked at the early effects 
of 670nm light treatment on the retinal transcriptome, which might be key in understanding the 
molecular mechanisms underlying its anti-inflammatory properties. Although, the exact 
underlying mechanism of this protective effect is unknown, current evidence suggests the 
involvement of cytochrome c oxidase (the primary photo-acceptor of 670nm light wavelength) 
and its downstream effects on mitochondrial membrane potential, cellular ATP production, cell 
signaling, and transcription [224, 239, 329-333].  
Members of our group have shown in the light-induced model of retinal degeneration that 
670nm is also able to modulate the noncoding RNA population, which in turn can act as potent 
regulators of gene expression. Additionally, we have recently shown in our light-induced 
model that there is significant modulation of microRNAs (a type of endogenous small 
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noncoding RNA molecule) in the retina. Indicating that these molecules might be able to 
modulate the inflammatory response during retinal degenerations [306].   
Due to the multifactorial and multigenic nature of the disease the pathophysiology of AMD 
remains to be clearly understood. However, extensive evidence over the years strongly supports 
the involvement of chronic inflammation in the pathogenesis of AMD, and several studies have 
documented the upregulation of inflammatory regulators including complement components, 
cytokines and chemokines in AMD patients [93, 334-338]. 
In this study we used the light-induced model of retinal degeneration to investigate the early 
effects of 670nm light irradiation on the inflammatory transcriptome of the retina, both coding 
and noncoding, to understand the potential molecular interactions at play. We also investigated 
the histology of the light damaged rat retina to identify any early structural changes occurring 
due to 670nm light.  
 
5.2 METHODS 
All methods are as mentioned in Chapter 2 of this thesis. Additional methods are as follows. 
5.2.1 ANIMALS, LIGHT DAMAGE AND 670NM TREATMENT 
All procedures conducted were in accordance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research. Adult Sprague-Dawley (SD) rats were born and 
raised in dim cyclic light conditions (5lux; 12hr on, 12hr off).  
Before exposure to bright damaging light for 24hrs, some animals were pre-treated with 670nm 
light using a WARP75 670nm LED array (QBMI Photomedicine, WI, USA) and some sham 
treated. Animals in the treatment groups were exposed to 9J/cm2 (3 minutes) of 670nm light 
daily for 5 consecutive days, according to the protocol detailed in chapter 2. Age matched dim 
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reared animals, either treated or sham treated with 670nm light were used as controls. Animals 
were culled after their respective treatment/light exposure conditions and retinal tissue obtained 
for further analyses. In the case of 670nm light treated only group animals were culled straight 
after the last 670 nm light treatment on the 5th consecutive day.       
5.2.2 TISSUE COLLECTION AND PROCESSING 
Animals were culled with an overdose of barbiturate injected intraperitoneally at 60mg/kg 
bodyweight. The left eyes of each animal were marked at the superior aspect and enucleated to 
be processed for cryosectioning, the retinas from the right eyes were extracted through a 
corneal incision and used for RNA extraction. Eyes for cryosectioning were immediately fixed 
in 4% paraformaldehyde for 3 hrs at room temperature and then processed as previously 
described [105], followed by cryosectioning at 16 µm. Retinas from the right eyes were 
immediately placed in RNAlater solution (Ambion), and stored according to manufacturer’s 
protocol. Total RNA was extracted from each sample and the concentrations determined using 
ND-1000 spectrophotometer (NAnodrop Technologies, Wilmington, USA).    
5.2.3 CELL DEATH ANALYSIS 
Cell death was assessed using the TUNEL technique on retinal cryosections using a previously 
published protocol [96]. The TUNEL-positive cells were counted across the retina in each of 
the experimental cohorts, as previously defined [306].   
5.2.4 QUANTITATIVE REAL-TIME PCR 
First strand cDNA synthesis was performed using TaqMan MicroRNA RT kit (Applied 
Biosystems) for miRNAs and Tetro cDNA synthesis kit (Bioline) for other genes, according to 
manufacturer’s protocols. Gene and miRNA amplification was measured using commercially 
available TaqMan hydrolysis probes (Table 5.1), according to a previously established qPCR 
protocol [306]. Fold change and hence percentage change was determined using the ΔΔCt 
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method, where miRNAs were normalized to U6 small nuclear RNA (snRNA) expression while 
chemokine genes were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
5.2.5 ONL AND RETINAL LAYER THICKNESS MEASUREMENT 
A DNA binding fluorescent dye bisbenzamide (Calbiochem, CA, USA) was used to visualise 
the cellular layers. ONL thickness was measured in increments of 1mm along the entire length 
on the retinal cryosection. Thickness was calculated as a ratio of ONL width to the distance 
between the outer and inner limiting membranes (OLM-ILM).  
Toluidine blue staining was used to assess the absolute thickness of all retinal layers. Sections 
used for staining were carefully selected to ensure that every group was measured at 
approximately the same retinal axis. Measurements were made at the point of localisation of 
the ‘hotspot’ (the part of the superior retina that is extremely susceptible to bright light 
damage). Multiple sections were measured for each animal and multiple animals were 
measured for each experimental group. Average values across each group were then plotted. A 
Two-way ANOVA analysis followed by bonferroni post hoc test was used for statistical 
analyses. 
5.2.6 IN SITU HYBRIDIZATION AND QUANTIFICATION OF CCL2-EXPRESSING 
NUCLEI 
To investigate the localisation and quantification of Ccl2 mRNA in the retina following 670nm 
light treatment and light damage, a DIG labeled riboprobe for Ccl2 (previously designed and 
used by members of our lab) was applied to retinal cryosections. Frozen retinal sections were 
thawed for 15-20 minutes at room temperature in a biological safety cabinet (class 2) before 
being dehydrated in 70% ethanol and rinsed in phosphate buffered saline (PBS).  
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Table 5. 1 
TaqMan® probes used 
Gene Symbol Name Accession # Catalog # 
Ccl2 Chemokine (C-C motif) ligand 2 NM_031530.1 Rn01456716_g1 
Ccl3 Chemokine (C-C motif) ligand 3 NM_013025.2 Rn00564660_m1 
Ccl4 Chemokine (C-C motif) ligand 4 NM_053858.1 Rn00587826_m1 
Ccl7 Chemokine (C-C motif) ligand 7 NM_01007612.1 Rn01467286_m1 
CxCL1 Chemokine (C-X-C motif) ligand 
1 
NM_030845.1 Rn00578225_m1 
CxCL10 Chemokine (C-X-C motif) ligand 
10 
NM_139089.1 Rn01413889_g1 
CxCL11 Chemokine (C-X-C motif) ligand 
11 
NM_182952.2 Rn00788262_g1 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
NM_017008.3 Rn99999916_s1 
IL1β Interleukin 1β NM_031512.2 Rn00580432_m1 
miR-351 mmu-miR-351 MIMAT0000609  001067 
miR-155 mmu-miR-155 MIMAT0000165  002571 
miR-124-3p mmu-miR-124-3p MIMAT0000422 001182 
miR-183 has-miR-183 MIMAT0000860  002269 
U6 U6 small nuclear RNA NR_004394 001973 
 
 113 
Sections were then fixed in 10% neutral buffered formalin (NBF) for 20 minutes, washed in 
PBS twice for 5 min each and then placed in a 20mg/ml Proteinase K (Roche) solution diluted 
in TE (50mM Tris-HCL, 5mM EDTA, pH 8) for 7 min at 37 °C. Sections were rinsed in PBS 
and re-foxed in NBF for 20 min. Slides were placed into a solution of 0.1M Triethanolamine 
(pH8.0, Sigma) and 2.5% acetic anhydride (Sigma) for 10 min, washed in PBS and then placed 
in 0.9% NaCl for 5 min. Thereafter, the slides were dehydrated through a series of increasing 
ethanol concentrations and air dried for 15 min. The prehybridisation solution was preheated 
to 58 °C on a heat block before being applied to the sections under a coverslip and incubated 
for 1 h at 55 °C. Following this, the coverslip was removed and preheated hybridization 
solution (containing the probe) was added to the sections under a new coverslip. Sections were 
hybridized in 100-300 ng of probe/ml overnight at 55 °C. The following day, coverslips were 
removed by immersing the slides in 4x saline sodium citrate (SSC, pH 7.4) at 60 °C. The slides 
were then washed in 2x SSC, 1x SSC, 0.1x SSC at 60 °C for 30 min each and washed in 0.1x 
SSC at RT for 5 min. Slides were rinsed in washing buffer, placed in blocking solution for 30 
min and then incubated with anti-DIG antibody (1:2000) for 1 h at RT. Following antibody 
incubation, slides were rinsed twice in washing buffer and once in detection buffer for 5 min 
each. Bound probes were visualised using an alkaline phosphatase conjugated secondary 
antibody and colorimetric AP substrate ‘NBT/BCIP’ (Sigma). The AP and substrate reaction 
was stopped by washing the slides in PBS for MQ Water for 10 min each. Slides were cover 
slipped using Aqua/Poly mount (Polysciences), sealed with nail varnish and visualised using 
bright field/light microscopy. 
Distinctive punctate labelling was counted as CCL2 positive cells across the retina. Counts 
were performed in a double blind setup where the individual slides were masked during the 
counting process. 4 sections were counted for each animal and a total of 5 animals were counted 
per experimental groups.  
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5.2.7 TAQMAN MIRNA ARRAY AND BIOLOGICAL FUNCTION ANALYSIS 
RNA from retinas of dim-reared, 670nm treated dim-reared animals was used for miRNA array 
analyses, according to previously described protocols [306]. Differentially expressed miRNAs 
between dim-reared and 670nm only treated samples were identified using 1-way ANOVA 
based statistical analysis provided within Partek® Genomic Suite 6.6 software. The biologic 
functional analysis for miR-351 was performed using DAVID® online functional classification 
tool. All predicted gene targets for miR-351, extracted from miRWalk™ database were 
imported into DAVID®s input portal and then the gene ontologies and pathway enrichments 
analysed for inflammation related processes. 
 
5.3 RESULTS 
5.3.1 QUANTIFICATION OF PHOTORECEPTOR DEATH AND CHANGES IN RETINAL 
THICKNESS: 
TUNEL analysis was used to assess the effect of 670nm light pretreatment on photoreceptor 
survival post light damage. Over a 1000 TUNEL+ photoreceptor cells were observed in the 
retina after 24hrs bright light exposure. While, pretreatment with 9J/cm2 670nm light 
significantly reduced this number of apoptotic photoreceptors to less than half as much 
(P<0.05) (Figure 5.1). However, 670nm light treatment alone had no significant effect on 
photoreceptor death relative to dim-reared controls. Additionally, ONL and other retinal layer 
thickness measurements were used to analyse the cumulative effect on photoreceptor death and 
changes to the retinal architecture following light induced stress (Figure 5.2). The average ONL 
thickness ratios across the retina did not change significantly between the different 
experimental groups (Figure 5.2A). Global retinal layer thickness measurements, however, 
revealed that bright light exposure by itself may be capable of causing expansion of the overall 
retinal thickness, compared to dim-reared retina (Figure 5.2B). With the ganglion cell layer 
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(GCL) and inner nuclear layer (INL) showing significant increase in thickness relative to dim-
reared control (P<0.05). In contrast, animals treated with 670nm light prior to light damage 
showed preservation of retinal thickness compared to the light damaged ones, and was 
comparable to the dim-reared animals (P>0.05). 
5.3.2 MODULATION OF CHEMOKINE-RELATED GENE EXPRESSION: 
We used qPCR to examine the effect of 670nm light on the expression of seven chemokines 
(CCL2, CCL3, CCL4, CCL7, CXCL1, CXCL10 and CXCL11). Expression of all seven 
chemokines increased significantly following light damage, compared to dim reared control 
(P<0.05, Figure 5.3). Chemokines CCL2 and CCL7 showed the most dramatic increase 
reaching a peak expression of 2,655- and 1,765-fold respectively, following 24hr light 
exposure. CCL3, CXCL1 and CXCL10 showed more modest increases of 263, 115 and 250 
fold, while CCL4 and CXCL11 only showed a 59 and 22 fold upregulation post light exposure. 
In animals treated with 670nm light prior to light damage, the expression of majority of the 
chemokines analysed was significantly lower than those subjected to light damage only (Figure 
5.3). Although, for both CXCL10 and CXCL11 expression appeared to be lower due to the 
670nm pre-treatment, the reduction was not statistically insignificant.  
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Figure 5. 1 Changes in photoreceptor cell death due to 670nm treatment 
Quantification of Photoreceptor cell death by TUNEL following 670nm light treatment and 
light damage. Increase in TUNEL+ cells in the ONL were observed after LD compared to both 
dim-reared and 670nm treatment only groups (P<0.05). Pre-treatment with 670nm light 
significantly reduced the number of TUNEL+ photoreceptors post LD. n=4 per experimental 
group; error bars represent SEM. (*) Indicates significance compared to dim-reared, unless 
when drawn in conjunction with comparison brackets, where (+) indicates significance 
between corresponding groups based on tukey’s post hoc test.    
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Figure 5. 2 Changes in retinal histology due to 670nm light treatment 
Measurements of ONL thickness ratio and individual retinal layer thickness following 670nm 
light treatment and light damage. (A) Graphical representation of ONL thickness ratio across 
the experimental groups along the length of the retina. No significant changes were observed 
in the ONL thickness among the different treatment groups across the entire retina. (B) Left: 
Graphical representation of the mean retinal depth. Only the GCL and INL show significant 
increase in thickness after LD compared to dim-reared control group (P<0.05), while 670nm 
light by itself or as a pre-treatment does not result in a significant change. Right: Representative 
image showing the measurement strategy for the retinal layer thickness. White lines indicate 
approximate boundaries between the retinal layers [the Outer segments (OS), inner segments 
(IS), outer nuclear layer (ONL), outer plexiform layer (OPL), inner nuclear layer (INL), inner 
plexiform layer (IPL), and ganglion cell layer (GCL)]. n=5; error bars represent SEM.  
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Additionally, chemokines CCL2, CCL7 and CXCL1 showed the most substantial reductions 
in expression, by approximately 50%, due to 670nm pre-treatment prior to light damage 
(P<0.05, Figure 5.3), compared to light damage alone. Of these, CCL7 was statistically 
indistinguishable from the dim-reared controls (P>0.05). No significant change in chemokine 
expression was observed in retinas treated with 670nm only, compared to the un-treated dim-
reared ones (P>0.05, Figure 5.3).  
5.3.3 LOCALISATION OF CCL2 MRNA IN THE RETINA POST LD AND 670NM LIGHT 
TREATMENT: 
Localisation of CCL2 expression in the retina was assessed using in situ hybridisation. CCL2 
was expressed in the retina by cells and their radial processes in the INL. In dim-reared animals, 
miniscule (near zero) amounts of CCL2 mRNA was observed in the retina (Figure 5.4A). Dim-
reared retinas treated with 670nm light did not show any significant differences in the number 
of INL cells expressing CCL2 compared to untreated control retinas (Figure 5.4C, Histogram). 
However, following 24hr bright light exposure there was a robust increase in the number of 
INL cells expressing CCL2, specifically in the superior part of the retina (Figure 5.4B). In 
contrast, in retinas pre-treated with 670nm light there were around 65% fewer INL cells 
expressing CCL2 compared with light damaged only retinas (Figure 5.4D, Histogram).  
5.3.4 MODULATION OF MICRORNA EXPRESSION WITH 670NM LIGHT PRE-
TREATMENT: 
Global miRNA profiling (of ~750 miRNAs) using low density arrays (LDAs) showed 
significant modulation of 8 miRNAs in the retina due to 670nm light treatment alone, 4 of 
which (miR-351, -542-3p, -449a and -467d) were also modulated in light damaged (alone) 
retinas (refer Chapter 3 Table 3.2).  
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Figure 5. 3 Effect of 670nm light treatment on the expression of α and β chemokines  
Comparative expression of α, β chemokines and IL1β in the retina by qPCR following 670nm light 
treatment and light damage. (A) Expression of α chemokines CCL2, 3, 4 and 7. (B) Expression of β 
chemokines CxCL1, 10 and 11. All chemokines increased significantly following light damage relative 
to dim-reared groups (P<0.05). Expression of all chemokines except CxCl10 and 11 were significantly 
reduced in animals pre-treated with 670nm light, relative to those light damaged only (P<0.05). Animals 
exposed to 670nm light only showed no significant change in chemokine expression compared to dim-
reared controls (P>0.05). (C) IL1β expression increased significantly following light damage relative 
to dim-reared group. 670nm light pre-treatment significantly reduced this upregulation, however, it still 
showed a significant upregulation compared to dim-reared (P<0.05). 670nm treatment only groups 
showed a substantial dowregulation of IL1β expression compared to dim-reared, however it did not 
achieve significance at the current sample size (P>0.05). All genes, except in the 670nm only group, 
were significantly modulated by experimental conditions compared to dim light conditions. n= 10 α-
chemokines genes; n=5 β-chemokines genes; n=5 IL1β; error bars represent SEM. Expression trend for 
all genes was significant based on 1-way ANOVA. (*) Indicates significance between the corresponding 
groups based on tukey’s post-test.   
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Figure 5. 4 CCL2 in situ hybridization and quantification of expression in the retina 
In situ hybridization for CCl2 mRNA in the retina following 670nm light treatment and light 
damage. (A-D) Representative images from the superior mid-peripheral region showing in situ 
hybridization for CCl2 mRNA in the retina. CCL2 expression was not detectable in retinas 
from dim-reared (A) and 670nm treated only (C) animals. In light damaged animals (B) 
numerous CCL2 expressing cells were observed throughout the inner nuclear layer (INL) 
(arrowheads), while significantly lower numbers were observed in those treated with 670nm 
prior to light damage (D). (Histogram) Quantification of CCL2 mRNA expressing cells per 
retina showed a drastic increase in LD animals relative to dim-reared and 670nm treated only 
groups (P<0.05). However, this increase was significantly reduced down to control levels in 
animals pre-treated with 670nm light prior to light damage (P<0.05). n=5; error bars represent 
SEM. (*) Indicates significance compared to dim-reared, unless when drawn in conjunction 
with comparison brackets, where (+) indicates significance between corresponding groups 
based in tukey’s post test.  
* 
* 
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Table 5. 2  
MiRNAs significantly modulated by 670nm treatment only 
miRNA ID P Value Fold Change 
mmu-miR-547 0.0346819 28.563 
mmu-miR-501-3p 0.0139051 26.0959 
mmu-miR-467d 0.0368586 14.667 
mmu-miR-449a 0.00919298 7.37819 
mmu-miR-345-3p 0.03215 5.50522 
mmu-miR-542-3p 0.0357811 4.36279 
mmu-miR-351 0.0283901 3.57415 
rno-miR-20b-3p 0.0394982 3.4851 
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These miRNAs were assessed using qPCR analysis (Figure 5.5 A-D), with only 2 (miR-351 
and -155) showing significant modulation due to 670nm light treatment. MiR-351 expression 
was significantly increased (~65%) in retinas treated with 670nm light alone, relative to the 
dim-reared and LD samples. MiR-155 was not modulated by 670nm treatment alone but was 
significantly reduced in light damaged retinas by 670nm pre-treatment, compared to the LD 
only samples. No other miRNAs were modulated by 670nm light treatment.  
Functional classification of the predicted targets for miR-351 was performed using DAVID® 
online algorithm (Figure 5.6). The analyses included “immune system process” as one of the 8 
gene ontology terms and “cytokine-cytokine receptor interactions” as one of the biological 
pathways involving the predicted gene targets of miR-351. Thirteen (13) genes appeared in 
both categories. 
 
5.4 DISCUSSION 
The results of this study show the efficacy of 670nm light treatment in suppressing early 
inflammation and chronic photoreceptor cell death following light induced retinal 
degeneration. First the findings indicate that irradiation with 670nm light reduces early 
photoreceptor cell death and suppresses the expansion in retinal thickness following bright light 
damage. Second, gene expression analyses indicate that pre-treatment with 670nm light 
downregulates a number of pro-inflammatory chemokines - including α-chemokines (CCL2, 
CCL3, CCL4, CCL7) and β-chemokines (CXCL1, CXCL10, CXCL11) - whose expression 
coincides strongly with photoreceptor cell death following light damage. Third, the results 
indicate that 670nm light pre-treatment has an effect on miRNA expression after light damage, 
with significant modulation of miR-155 and miR-351 detected.  
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Figure 5. 5 Changes in expression of specific miRNAs due to 670nm light treatment  
Expression profile of miRNA in the retina by qPCR following 670nm light treatment and light 
damage. (A) MiRNA showing significant modulation due to 670nm light treatment alone, (B) 
Modulation of pro-inflammatory miRNAs due to 670nm pre-treatment, (C) Modulation of a 
CNS specific anti-inflammatory miRNA and (D) Modulation of a photoreceptor specific 
miRNA. MiR-351 was significantly upregulated due to 670nm treatment itself. The increase 
in pro-inflammatory miRNA, miR-155 was significantly suppressed with 670nm pre-treatment 
(P<0.05). 670nm treatment given alone or as a pre-treatment to LD had no impact on the 
expression profile of miR-124 or miR-183 (P>0.05). n=6; error bars represent SEM. (*) 
Indicates significance compared to dim-reared, unless when drawn in conjunction with 
comparison brackets, where (+) indicates significance between corresponding groups based on 
tukey’s post test. 
 
* * 
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Figure 5. 6 Potential functional impact of miR-351  
Functional analyses of miR-351 predicted targets using DAVID® functional annotation 
database. All predicted gene targets for miR-351 were analysed using an analytical algorithm 
to identify the functional categories most highly affected by these genes and hence potentially 
by miR-351. The GO term classification revealed ‘immune system process’ as one of the major 
biological processes enriched, while the pathway analyses revealed ‘Cytokine-Cytokine 
receptor interaction’ as a highly represented pathway potentially being targeted by miR-351. 
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Both miR-155 and miR-351 have predicted binding sites for a number of inflammatory 
molecules, including those that work upstream of chemokine expression, suggesting a possible 
mechanism by which 670nm influences the retinal immune response.  
Previous investigations have shown that irradiation with 670nm light reduces photoreceptor 
cell death, complement propagation and activated microglial accumulation in the retina during 
prolonged periods following light-induced damage [118, 233, 236]. In the current study, 
however, we show some of the early changes in the retinal transcriptome due to 670nm pre-
treatment, including inhibition of chemokine genes that have previously been shown to 
upregulate in the light damaged retina by several PCR and microarray based studies [96, 99, 
272, 273, 339].  
In the present study we demonstrated using TUNEL analysis that 670nm light irradiation 
inhibits the early initiation of photoreceptor cell death due the damaging light exposure. While 
no change is seen in the ONL thickness (a measure of cumulative effect of photoreceptor cell 
death) across the different experimental groups. Suggesting that photoreceptor death might 
only have a significant impact on ONL thickness at higher levels or a more sustained period of 
low level death, as is documented in previous studies focusing on the long term effects of light 
induced retinal degeneration [105, 118, 236]. Our data indicates that TUNEL analysis is a more 
robust tool for detecting the neuroprotective effect of 670nm light on photoreceptor cells at the 
early damage time points such as the one under consideration here. To further characterise the 
impact on the retinal architecture we used haematoxylin and Eosin stained retinal cross sections 
to measure the absolute thickness of the different retinal layers. As evident in figure 5.2B we 
saw a slight increase in the overall retinal thickness, with significant increases in the GCL and 
INL widths. Suggesting that cells in these layers may be the first to respond to the damaging 
stimulus. The INL contains the cell bodies of Müller cells, the site of expression of CCL2 post 
light damage, hence the increase in its width could be attributed to the movement of 
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inflammatory cells including microglia and monocytes into the INL. While the expansion in 
GCL width could potentially arise from an increase in infiltration of inflammatory cells from 
the retinal vasculature. This data, however, is not corrected for the variability in sectioning 
obliqueness, which can lead to incorrect layer thickness measurements. It would hence be better 
to flat mount the retina before embedding and cutting to reassess absolute thickness changes.  
Chemokines are a well-established family of genes/proteins that possess potent 
chemoattractant properties and drive targeted recruitment of leukocytes during immune 
surveillance as well as inflammation [87, 88, 90, 340]. Several studies have shown the 
upregulation of a number of chemokines following light damage, with a recent study 
identifying the source of each different chemokine in the light damaged rat retina [99]. 
Similarly, our data also shows significant upregulation of a subset of these molecules following 
light damage. Moreover our findings indicate that their expression profile correlates with the 
pattern of photoreceptor cell death following light damage.  
In contrast, retinas pre-treated with 5x 9J/cm2 670nm light show a significant reduction in the 
respective upregulation post light damage for all chemokines except CXCL10 and CXCL11. 
Although, their expression trend across the different experimental groups was still significant 
based on a 1-way ANOVA test. Among the significantly downregulated chemokines were 
CCL2, CCL3, CCL4, CCL7 and CXCL1, all of which are believed to form a complex network 
of activity post stimulation by light-induced retinal damage and are expressed by specific cell 
types of the retina.  While the exact roles of most of these molecules in the degenerating retina 
are still unclear, studies in other diseases/disease models might be useful in highlighting their 
potential roles.   
For instance CCL3 and CCL4, which are specifically expressed by activated microglia in the 
retina, are capable of monocyte recruitment and Th1 T cell mobilisation via interactions with 
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Ccr1, Ccr5 receptors [341-345]. CCL7, expressed by Müller cells and activated microglia, acts 
as an agonist for the well documented Ccr2 receptor, a key player in monocyte chemotaxis 
[346, 347]. In contrast CXCL1, which is expressed by both Müller cells and RPE, plays a role 
in neutrophil recruitment from the surrounding vasculature along with its receptor Cxcr2 [348-
350]. This is of particular interest as neutrophils have been shown to be involved in the 
pathophysiology of choroidal neovascularisation [351]. While CCL2, expressed by Müller 
cells and infiltrating monocytes in the damaged retina, is a well-documented retinal chemokine 
with potent chemoattractant properties that drive targeted recruitment of macrophages [97, 98, 
352, 353]. 
The CCL2 in situ data presented in this study indicate that its downregulation induced by 
670nm pre-treatment is due to reduced expression of CCL2 by Müller cells, and not simply a 
consequence of reduced infiltration of activated CCL2-expressing monocytes from the choroid, 
which has been shown to occur due to 670nm pre-treatment [118, 236]. Together, the findings 
suggest that 670 nm light pre-treatment can suppress CCL2-mediated recruitment of blood-
borne monocytes as well as the broader leukocyte population into damaged regions of the retina 
after bright light exposure. This effect mitigates the progressive degenerative state of the retina 
that promotes photoreceptor cell death. 
 Mechanistically, this broad spectrum inhibition of inflammatory regulators by 670nm light 
treatment could be explained by its ability to enhance mitochondrial function which leads to 
increased ATP production and reduction of oxidative stress [214, 236, 239]. Alternatively, this 
could potentially be explained by a relatively new hypothesis gaining momentum in the recent 
past whereby, photobiomodulation is able to increase the bioavailability of nitric oxide (NO), 
a potent intracellular messenger that could act as a downstream signalling molecule leading to 
differential effect on the cellular transcriptome [250, 251, 354, 355]. Various in vitro and in 
vivo studies suggest that 670nm treatment increases NO availability either by stimulating 
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inducible nitric oxide synthase (iNOS) expression or by causing the dissociation of NO from 
cytochrome c oxidase in the mitochondria [210, 356-360].   
5.4.1 MIRNA EXPRESSION PROFILE 
A previous gene expression study showed that 670nm light irradiation modulates noncoding 
RNAs as well as protein coding mRNAs [96]. Here, the modulation of miRNAs was assessed 
to better understand the potential molecular mechanisms by which 670nm light might modulate 
retinal inflammation.  
The present findings indicate that 670nm light on its own may modulate miRNAs in the retina 
(see Table 5.2) and that some of these are also modulated by light damage (refer Chapter 3). 
However, the qPCR analysis was not entirely confirmatory in that miR-351 showed a non-
significant change in the light damaged retinas compared to the low density array results. This 
variability could be explained by the biological differences inherent in the light damage model 
in which some animals respond more severely to others [361, 362].  
More importantly, however, there is a consistent and significant upregulation in miR-351 due 
to 670nm treatment only. While not much is known about its role in inflammation associated 
with AMD or light-induced retinal degeneration, we found predicted binding sites for miR-351 
in the 3’UTR of a number of pro-inflammatory factors including potent chemokine regulators 
IL1β and TNF. Both have been implicated in AMD and retinal degenerations [281, 363-368]. 
Both IL1β and TNFα (a common form of TNF) are upregulated as early as 12 hours post bright 
light exposure in this model, prior to upregulation of a gamut of pro-inflammatory chemokines 
that reach peak expression at 17-24 hours exposure to bright light [99]. In this study we find 
that the upregulation of IL1β is significantly reduced by 670nm light pre-treatment consistent 
with its favourable effects on neuroinflammation. However, because the interaction between 
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miR-351 and IL1β is only a predicted phenomenon further confirmation using luciferase-based 
assays are required.  
The findings also demonstrate an effect of 670nm light treatment on the modulation of a well-
known pro-inflammatory miRNA miR-155, which has previously been shown to upregulate 
post light-induced damage [306].  
MiR-155 is upregulated by light damage, but did not show a significant modulation due to 
670nm treatment alone. While it was maintained at control levels in light damaged retinas pre-
treated with 670nm light (Figure 5.5B). Since the tissue/cellular localisation of miR-155 in the 
light damaged albino rat retina is currently unknown, it is difficult to speculate how its 
expression is being modulated. However, studies in other disease models have shown that both 
resident microglia and infiltrating monocytes stimulated with pro-inflammatory cues (such as 
TNFα and IL1β) exhibit an upregulation of miR-155 which in turn supports the activation of 
their M1 or pro-inflammatory state.  
Additionally, previously published work from our group has shown that 670nm pre-treatment 
significantly reduces the upregulation of various pro-inflammatory factors (cytokines, 
chemokines) and microglia/monocyte recruitment in the retina post LD. Hence, the lack of 
miR-155 upregulation (relative to dim reared control) in the 670nm pre-treated light damaged 
retinas could possibly result from either:  
1. Little or no stimulation of microglia/monocytes in the absence of a pro-inflammatory 
microenvironment, as a result of 670nm pretreatment. OR  
2. Reduced recruitment of M1 microglia/monocytes to the retina.  
None the less, this result is particularly interesting as miR-155 has recently been shown to 
target complement factor H (CFH) [199], which is strongly associated with the risk of AMD 
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[369]. The findings indicate that treatment with 670nm light to reduce levels of miR-155 may 
result in increased levels of CFH in the retina, leading to down modulation of complement.  
In contrast, miR-124 expression was not modulated by 670nm light treatment, even after light 
damage (Figure 5.5C). Since miR-124 inhibits CCL2 expression by direct binding [305], this 
observation suggests that anti-inflammatory effects of 670nm light are upstream or independent 
of CCL2 regulation via miR-124-3p. It is possible that the relatively small inflammatory 
response elicited in 670nm + LD retinae is still sufficient to exhaust the amount of 
endogenously expressed miR-124-3p, and that the downregulation of CCL2 seen due to 670nm 
pre-treatment is a consequence of a secondary mechanism.  
The findings for miR-183 were similar in that a downregulation of miR-183 expression was 
detected post LD, with or without pre-treatment with 670nm light. The data, however, indicate 
a trend toward 670nm light influencing this downregulation, at marginal levels of significance. 
MiR-183 cluster is highly specific to the sensory organs and regulates the retinal circadian 
rhythm [296, 370]. Knockdown and knockout studies in the mouse retina have shown a 
protective role of the miR-183 cluster against light induced damage [295, 371], while several 
studies in other disease models have identified disease promoting effects of the miR-183 cluster 
in neurodegeneration [372, 373] and cancer [374-379]. The effects of miR-183 here may be 
due to the ability to potentially alter energy metabolism as a result of its affinity for isocitrate 
dehydrogenase 2 (IDH2), an essential mitochondrial enzyme [378].  
5.4.2 CONCLUSIONS 
The findings presented in this chapter indicate that 670nm irradiation significantly reduces the 
early stimulation of chemokine synthesis and photoreceptor cell death in the retina following 
light-induced damage. The results also indicate that 670nm light treatment may modulate the 
miRNA transcriptome of the retina. Such modulation is a potential mechanism by which 
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670nm light modulates inflammatory regulators and inflammation in the retina. However, the 
data also suggest that the key pro-inflammatory chemokine, CCL2, is not modulated by 
changes in expression levels of miR-124-3p in the presence of 670nm light. An essential 
strategy to progress these studies is the use of crosslinking immunoprecipitation in conjunction 
with high-throughput RNA sequencing, to identify all the functionally active miRNA:mRNA 
interactions in the retina during both normal and degenerative states.       
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CHAPTER 6: SUMMARY AND 
CONCLUSIONS 
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In this thesis I explore the concept that miRNA play a role in retinal degenerations and that 
their further study might elucidate potential therapeutic interventions. Firstly, using a LD 
model of retinal degeneration I show that miRNA are differentially expressed over a protracted 
time course, and that many of these miRNA regulate inflammatory genes and processes. 
Secondly, I identified a novel retinal miRNA, miRNA-124-3p, as a potential modulator of the 
pro-inflammatory state of the retina post light damage, and which may be therapeutically 
targeted to ameliorate inflammation during retinal degenerations. Finally, I show that some 
miRNA are modulated by 670nm red light, including two involved in modulating inflammatory 
genes. This finding reinforces the anti-inflammatory potential of 670nm red light, while also 
identifying other candidate miRNAs, specifically miR-155 and miRNA-351, as potential 
therapeutic targets.  
In the past decade, studies have shown the modulation of miRNAs (including miR-124-3p) in 
the developing mammalian retina [314, 370, 380-382] in a strict spatiotemporally distributed 
profile, suggesting a tight transcriptional control of expression. Many studies have focused on 
the pathological roles of miRNAs using animal models of retinal disorders including diabetic 
retinopathy and retinitis pigmentosa [383-387]. In this study significant modulation of miRNAs 
is identified in a light damage model of focal retinal degeneration. Many of the miRNAs 
identified regulate the inflammatory response, relevant in AMD. MiRNAs have recently gained 
momentum with regards to their therapeutic potential in AMD, with a recent study by Lukiw 
and colleagues [199] showing a direct link between upregulation of 4 miRNAs (miR-9, -125b, 
-146a and -155) and downregulation of complement factor H (CFH) expression in human post-
mortem retinal tissue. Additionally, several other studies have identified a number of miRNAs 
as potential therapeutic targets for AMD (reviewed in [388]).   
Because miRNAs are endogenous, and function as master regulators of gene expression and 
multiple biological pathways, they are highly attractive therapeutic target for complex diseases. 
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In other biological systems, some miRNA-based therapies have already entered clinical trials 
including an anti-miR-122 therapy to efficiently target hepatitis C virus infection, and an 
miRNA replacement therapy using a miR-34 mimic for its strong anti-tumour activity targeting 
primary liver cancer / solid tumours / haematological malignancies [203, 204].   
Ongoing work investigating the function of miRNAs identified in the present study, and others, 
is required to better understand their role/s in the onset and progression of retinal degeneration. 
One approach is through the use of intravitreal injections of specific miRNA mimics or 
inhibitors to enhance or supress a miRNAs function.  A lipid-based transfection method 
(Invivofectamine ® 1.0) was successfully used in the past in our research group to deliver 
siRNA [97]. Using a similar approach I attempted transfection of a miR-124-3p mimic into the 
rat retina, using Invivofectamine ® 2.0. However, the experiments had to be abandoned 
because our data indicated that the transfection agent was triggering a non-specific immune 
response, masking any effect of miR-124-3p. Our research group is currently testing a new 
transfection agent produced by the manufacturers ThermoFisher ™. The mimic / inhibitor 
experiments will be resumed once we are satisfied that the transfection agent does not induce 
a biological response. Unfortunately, completion of those experiments will be outside the 
period of candidature for my PhD.  
One of the inherent properties of miRNA biology is that they target many different genes 
simultaneously. This is a possible hindrance of using miRNAs for therapeutics as it raises 
questions about potential off-target interactions of mimics and inhibitors. To that end, recent 
advances in molecular techniques include comprehensive multi-strategy assays to help identify 
all active miRNA:mRNA interactions occurring inside the cell with high confidence. One such 
assay is HITS-CLIP, employing high-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation, whereby miRNA:mRNA complexes bound to Argonaute 2 (a component 
of the RNA-induced silencing complex) are crosslinked using ultraviolet light, and pulled down 
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using anti-AGO2 antibody [389]. This powerful technique can identify all tissue/condition 
specific miRNA targets, thereby assisting in characterising potential off-target interactions at 
any given condition. This inherent property of miRNA, however, is also a major benefit when 
using them to treat complex multifactorial diseases such as AMD that require modification of 
multiple cellular processes simultaneously.  
MiRNAs are potent regulators of the genome and clearly have a role in retinal degenerations 
through modulation of the local inflammatory response. The results presented in this thesis 
provide a basis for understanding the potential role of miRNAs in regulating the innate immune 
response during retinal degeneration. The similarity in the profiles of miRNA modulated in the 
LD model, and those identified in AMD provides support for the use of the LD model in 
understanding processes of retinal inflammation relevant to AMD. Further work is warranted 
to characterise the role/s of these putative candidates in retinal inflammation, including 
identification of off-target effects and possible synergies, to transform the basic knowledge 
described here into effective clinical therapies.   
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Table: mRNA targets of the differentially expressed miRNAs 
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